# AMT Mortgage Insurance Ltd.

Solvency and Financial Condition Report For the year ending 31 December 2018

> a must ingresses that the fullerwitting threat and the second south and the second second second second second second south and second second

repair made ne result à la repair of damage in pur purpose other that white spair due to electrical dama l'repair made necessary to easonable opinion of Sa Seller may advise the Cur





# Contents

Summa	ıry	2
A. Bu	siness and Performance	8
A.1	Business	9
A.2	Underwriting Performance	
A.3	Investment Performance	
A.4	Performance of other activities	
A.5	Any other information	
	stem of Governance	
B.1	General information on the system of governance	
B.2	Fit and Proper Requirements	
В.2 В.3	Risk management system including the own risk solvency assessment	
в.з В.4	Internal control system	
B.5	Internal audit function	
B.6	Actuarial function	
B.7	Outsourcing	
C. Ris	k Profile	26
C.1	Underwriting risk profile	
C.2	Market risk	
C.3	Counterparty default risk	
C.4	Liquidity risk	
C.5	Operational risk	
C.6	Other material risks	
C.7	Any other information	
D. Va	luation for solvency purposes	
D.1	Assets	33
D.2	Technical Provisions	
D.3	Other liabilities	
D.4	Alternative methods for valuation	
D.5	Any other information	
	pital Management	
E.1	Own funds	
E.2	Solvency capital requirement and minimum capital requirement	
E.3	Use of duration-based equity risk sub-module in the calculation of Solvency Capital Rec	
E.4	Difference between the standard formula and the internal model used	
E.5	Non- compliance with the Minimum Capital Requirement and non-compliance with the	
	irement	
E.6	Any other information	
F. Ar	inex	47



### Summary

The principal activity of AMT Mortgage Insurance Limited (AMIL or "the Company") is the underwriting of general insurance business across Europe, insuring mortgage lenders in respect of borrower default.

Branches have been established in Germany, Ireland, Italy, and Spain, where the Company also has Prudential Regulatory Authority (PRA) approval in the United Kingdom to write business directly. In addition, the PRA has approved business to be written by way of freedom of services from the UK for Ireland, Finland, Denmark, Hungary, Germany, Austria, Poland, France, Sweden, Portugal and Belgium. At present, the Company is actively writing new business in Germany, Italy and the UK, with run off portfolios in Ireland, Portugal, Spain, Finland and Sweden.

The Company is proceeding with Part VII transfer of its business to its parent company AmTrust Europe Limited and other group companies, expected to be completed by 2020, with an intention to then liquidate the Company in due course. This will lead to greater efficiencies for the AmTrust group and conclude a full integration of this business into their existing structure. Consequently, the Company now underwrites new transactions on other rated balance sheets within the AmTrust Group. The Credit Default business produced and underwritten by the Company will continue to be serviced by the same operational team due to it being a niche insurance product requiring bespoke knowledge.

The Company's focus is on the growth of the business under the right conditions as the Company works to take advantage of positive market conditions and future regulatory improvements, management of the in-force book of business and strong risk and capital management.

The company's functional currency is Euro due to most business being written in Euro denominated territories and its financial statements are also presented in that currency. For this SFCR, the directors have chosen to use GBP as the presentation currency.

The amount of Net Written premium (NWP) gross of reinsurance outward decreased from  $\leq 16,251,000 \sim \pm 14,235,000$  in 2017 to  $\leq 11,223,000 \sim \pm 9,930,000$  in 2018. Net Earned premium decreased from  $\leq 13,074,000 \sim \pm 11,452,000$  in 2017 to  $\leq 9,391,000 \sim \pm 8,309,000$  in 2018.

During the year, the Company undertook one significant partial commutation of insurance liabilities with an active customer and also a number of smaller commutations.

The Company will continue to pursue a policy of encouraging settlements on populations of loans with lenders where it is economically sensible to do so. The Company also continues to work actively with lenders to mitigate the impact of ageing delinquencies through a work-out programme "tool-box", whereby adjustments made by lenders to mortgage terms are agreed to allow borrowers to meet contractual obligations but maintain mortgage insurance cover.

The loss ratio decreased from 43% in 2017 to 16% in 2018 mainly due to non-renewal of XOL treaty in 2018. Paid claims were €8,883,000 ~ £7,859,000 (2017: €6,377,000 - £5,589,000), 2018 includes €8,075,000 ~ £7,144,000 in respect of commutations in Italy whereas 2017 includes €5,175,000 ~ £4,536,000 in respect of commutations in Finland, Italy, Portugal and UK.


Overall the Risk in Force (which represents the full aggregate of Insurance exposure from the Company's coverage) decreased to €2.1BN (2017: €2.3BN).



# **Governance Structure**

The Company's overall governance structure:

Dual Purpose (Management and Governance)



### **Risk Profile**

#### The Company's Key risks:

- Underwriting Risk
- Market risk
- Credit Risk
- Liquidity Risk
- Operational Risk
- Other Risks, including:
  - Legal and regulatory
  - Strategic
  - Governance
  - Group
  - Solvency



#### Key Valuation Differences

Valuation differences arise due to the difference between Solvency II fair value rules and UK GAAP. The table below highlights the differences between the solvency II economic balance and the statutory accounting balance sheet. These valuation and classification differences are further explained in Section D.

Category	31.12.2018 Solvency II (£'000)	31.12.2018 UK GAAP (£'000)	Difference
Deferred Acquisition Costs	0	2103	(2,103)
Property, plant & equipment held for own use	19	19	0
Investments (other than assets held for index-linked and unit-linked contracts)	124,888	123,202	1,686
Reinsurance recoverables	3,741	15,062	(11,321)
Insurance and intermediaries receivables	1,708	7,074	(5,366)
Reinsurance receivables	467	3,254	(2,787)
Receivables (trade, not insurance)	55	55	0
Cash and cash equivalents	4,094	4,097	(3)
Any other assets, not elsewhere shown	0	812	(812)
TOTAL ASSETS	134,972	155,678	(20,706)
Technical provisions - non-life (excluding health)	46,486	65,467	(18,981)
Reinsurance payables	1,763	6,430	(4,667)
Payables (trade, not insurance)	11,634	11,634	0
TOTAL LIABILITIES	59,883	83,531	(23,648)
Excess of Assets over Liabilities	75,089	72,147	2,942



#### Composition of Own Funds

£'000	Dec 2018	Dec 2017
Ordinary share capital	67,688	67,688
Reconciliation reserve	7,401	7,388
Own funds	75,089	75,076

Note, of the above Own Funds, all are Tier 1, and 100% eligible towards the Company's SCR and MCR.

None of the Company's Own Funds are subject to transitional arrangements. There are no Ancillary Own Funds. There are no ring-fenced funds and no deductions are made from Own Funds, nor is there any restriction affecting the availability and transferability of Own Funds within the Company.

Material differences between equity in the financial statements, and the excess of assets over liabilities:

£'000	Dec 2018	Dec 2017	Dec 2016
Total reserves and retained earnings from UK GAAP Financials	72,147	71,410	112,431
Differences arising from SII Valuation of assets	(20,706)	(18,469)	(20,689)
Differences arising from SII Valuation of technical provisions	18,981	17,144	(320)
Differences arising from SII Valuation of other liabilities	4,667	4,991	3,549
Own funds per Solvency II	75,089	75,076	94,971

Capital Requirements £'000	31 December 2018	31 December 2017	31 December 2016
SCR	35,468	43,320	46,034
MCR	8,866	10,829	13,698



# Directors' statement of responsibilities in respect of the SFCR

The Board acknowledges its responsibility for preparing the SFCR in all material respects in accordance with the PRA rules and the Solvency II Regulations which includes preparing the SFCR on the going concern basis unless it is inappropriate to presume that the Company will continue in business. As explained in A1.7 – Material Events, of the SFCR, the directors do not believe it is appropriate to prepare this SFCR on a going concern basis.

The Board is satisfied that:

- throughout the financial year in question, AMIL has complied in all material respects with the requirements of the PRA Rules and the Solvency II Regulations as applicable to the AMIL; and
- it is reasonable to believe that the insurer has continued so to comply subsequently and will continue so to comply in the future.

The SFCR was approved at a meeting of the Board of Directors on 4<sup>nd</sup> April 2019 and signed on its behalf by:

Angel Mas Murcia 04 April 2019





# Report of the external independent auditor to the Directors of AMT Mortgage Insurance Limited ('the Company') pursuant to Rule 4.1 (2) of the External Audit Chapter of the PRA Rulebook applicable to Solvency II firms

#### Report on the Audit of the Relevant Elements of the Solvency and Financial Condition Report

No external Independent audit was performed. As per the PRA policy statement 25/18, AMIL is exempt from the audit requirement of its Solo SFCR.

# **Business and Performance**

Section A



# A. Business and Performance (unaudited)

A.1.Business

#### A.1.1. Name and legal form of undertaking

AMIL is a company limited by shares (Company Number 2624121), authorised and regulated by the Prudential Regulation Authority (PRA) and the Financial Conduct Authority (FCA) to carry out general insurance activities within the UK and European insurance markets. AMIL writes only one class of insurance business, credit and suretyship, hence is also referred to as a "mono-line" insurer (this refers to only writing a single class of business; credit and suretyship).

The Company's registered address is as follows:

AMT Mortgage Insurance Limited (AMIL) 33 St Mary Axe, London, EC3A 8AA

#### A.1.2. Supervisory authority

AMIL is regulated by the Prudential Regulation Authority (PRA). The PRA was created as a part of the Bank of England by the Financial Services Act (2012) and is responsible for the prudential regulation and supervision of banks, building societies, credit unions, insurers and major investment firms. The PRA's objectives are set out in the Financial Services and Markets Act 2000 (FSMA).

The PRA's registered address is as follows:

Prudential Regulation Authority, Bank of England, Threadneedle St, London, EC2R 8AH Tel 020 7061 4878 enquiries@bankofengland.co.uk

AMIL belongs to the AmTrust International Ltd (AIL) group of companies. The Group is also supervised by the PRA.

AMIL is also regulated by the Financial Conduct Authority (FCA).

The FCA's registered address is as follows:

Financial Conduct Authority, 12 Endeavour Square Stratford E20 1JN

#### A.1.3. External auditor

AMIL, together with the wider AmTrust Group, is audited by KPMG. KPMG's UK office is located at:

KPMG LLP, 15 Canada Square, London, E14 5GL Tel 020 7311 1000

#### A.1.4. Shareholders of qualifying holding in the undertaking

AMIL is a wholly owned subsidiary of AmTrust Europe Limited (AEL or the Group) which is a UK Limited Company.

Until 29th November 2018, AMIL's ultimate parent was AmTrust Financial Services Inc (AFSI), a Delaware registered US corporation. On 29th November 2018, a merger transaction was completed in which Evergreen



Parent GP, LLC, an entity formed by private equity funds managed by Stone Point Capital LLC ("Stone Point"), together with Barry Zyskind, Chairman and CEO of AmTrust, George Karfunkel and Leah Karfunkel (collectively, the "Karfunkel-Zyskind Family"), acquired the approximately 45% of AFSI's issued and outstanding common shares that the Karfunkel-Zyskind Family and certain of its affiliates and related parties did not already own or control.

This go-private transaction was a strategic step to focus on the operational excellence of AmTrust and implement the long-term strategies that position the group for future success.AFSI underwrites and provides property and casualty insurance products, in the United States and internationally to niche customer groups that it believes are generally underserved within the broader insurance market.

As a subsidiary of AmTrust Financial Services Inc. the Company benefits from financial, operational and management support. AFSI is a multinational property and casualty insurer specialising in small to medium sized businesses. With extensive underwriting experience and a prestigious "A-" (Excellent) Financial Size "XIV" rating from A.M. Best, AFSI has earned a reputation as an innovative, technology driven provider of insurance products. Commitment to excellence is a common thread connecting each of the AmTrust companies.


AFSI's business model focuses on achieving targeted returns and profit growth with the careful management of risk. The Global Group pursues these goals through geographic and product diversification, as well as an in-depth understanding of its insured exposure. The product mix includes, primarily: workers' compensation; extended warranty; and other commercial property/casualty insurance products, including title insurance and crop insurance. Workers' compensation and property/casualty insurance policyholders in the United States are generally small and middle market businesses. Extended warranty customers are manufacturers, distributors and retailers of commercial and consumer products. AmTrust has also built a strong and growing distribution of extended warranty and specialty risk products, including liability and other property/casualty products, in Europe.

AmTrust International Limited (AIL) is the UK holding company for AFSI's European insurance operations, whose principal entities are: AmTrust Europe Limited (AEL); Car Care Plan Holdings, including Motors Insurance Company Ltd. (MICL); AmTrust Syndicate Holdings Ltd. (ASH); and AMT Mortgage Insurance Ltd (AMIL, previously "Genworth Financial Mortgage Insurance Ltd."). AIL also owns a number of administrators in the UK and Asia.

#### A.1.5. Position within the legal structure of the group

The following simplified group structure chart shows where AMIL sits within the wider AFSI group.







#### A.1.6. Material lines of business and material geographical areas where AMIL carries out business

The principal activity of the Company is the underwriting of general insurance business in the United Kingdom and other European countries. The Company is a mono-line insurer and writes solely credit and suretyship business, specifically mortgage insurance. This is "B2B" business where the Company insures the lender against mortgage default.

#### A.1.7. Material events

The following material events impacted the Company during the year:

- Brexit vote During 2016, the United Kingdom voted to leave the European Union. The Company expects the Solvency II requirements to remain, both in the short term during the negotiations of the UK's exit and in the long term, through the granting of formal equivalence status, i.e. legislation passed to make solvency regulations in the UK equivalent to Solvency II. The Company, together with the AIL Group, have been looking at possible ways of minimising the impact to its clients, operations, and business opportunities of the Brexit vote by reviewing various strategic options. The main risk to the Company is the ability of the company to migrate new business from its existing clients to other group companies within any deadlines or under any restrictive servicing rules as yet undecided under the detailed terms of the UK leaving the European Community. The Company has already ceased to take on new clients from the European Community, and is placing such new business from existing European Community clients to other group companies in preparation of Brexit.
- Renewal of Quota Share reinsurance AMIL has a quota share reinsurance programme with a panel of reinsurance companies all A rated (AM Best, S&P, and Moody's) or better. This program was started in the 2011 year and was in place in 2018 at 33.33% each year and is renewed for 2019 at 50%. The increase for 2019 is driven by the AmTrust's strategy of protecting its longer tail risk.
- Part VII Business transfer During 2017, the Company initiated the Part VII transfer process of its entire business to its parent company AmTrust Europe Limited and other group companies, possibly to be completed by 2020, with an intention to then liquidate the Company in due course. Having assessed the situation, the Board believes that the Company is no longer a going concern and accordingly this SFCR should be prepared on the Break-up basis. This has no impact on the Company's carrying value of the assets and liabilities included in this SFCR as the transfer of assets and liabilities to Company's parent company is expected to happen at their carried values.



# A.2. Underwriting Performance

### A.2.1. Material lines of business

Credit & Suretyship	2018	2017
£'000		
Gross premiums written	9,930	14,235
Reinsurers' share	(3,206)	<u>(7,541)</u>
Net premiums written	6,724	<u>6,694</u>
Gross premiums earned	12,356	19,424
Reinsurers' share	(4,047)	(7,972)
Net premiums earned	8,309	11,452
Gross claims incurred	(2,080)	(4,972)
Reinsurers' share	745	4
Net claims incurred	(1,335)	(4,968)
Net operating expenses	(5,715)	(5,758)
Other	396	<u>149</u>
Net technical result	1,655	876
Net Investment Result	368	1,359
Other	(403)	1,312
Profit on ordinary activities	1.000	3,547
before tax	1,620	·
	l l	
Тах	(335)	(272)
Profit for the financial year	1,285	3,275

#### A.2.1.1. Credit and Suretyship

The principal activity of the Company is the underwriting of general insurance business across Europe, insuring mortgage lenders in respect of borrower default. The company is a mono-line insurer, and writes solely "B2B" (Business to Business) insurance products.

Performance in 2018 was better than planning expectations. During the year, the Company made a profit of £1,285,000 driven by proactive management of client portfolio and better expense management.

The loss ratio decreased from 43% in 2017 to 16% in 2018 mainly due to non-renewal of XOL treaty in 2018. Paid claims were €8,883,000 ~ £7,859,000 (2017: €6,377,000 - £5,589,000), 2018 includes €8,075,000 ~ £7,144,000 in respect of commutations in Italy whereas 2017 includes €5,175,000 ~ £4,536,000 in respect of commutations in Finland, Italy, Portugal and UK.



# A.2.2. Material geographic areas

Performance in the top 3 countries in which AMIL operates is summarised in the table below.

2018	United Kingdom	Italy	Germany	Other EU
	£'000	£'000	£'000	£'000
Gross premiums written	1,194	6,279	1,786	671
Reinsurers' share	(397)	(2,249)	(556)	(4)
Net premiums written	797	4,030	1,230	667
Gross premiums earned	1,477	8,741	1,256	882
Reinsurers' share	(487)	(3,023)	(527)	(10)
Net premiums earned	990	5,718	729	872
Gross claims incurred	67	(2,377)	(189)	419
Reinsurers' share	0	745	0	0
Net claims incurred	67	(1,632)	(189)	419
Net operating expenses	(386)	(3,718)	(418)	(1,193)
Other	47	272	35	42
Technical Result	718	640	157	140

2017	United Kingdom	Italy	Germany	Other EU
	£'000	£'000	£'000	£'000
Gross premiums written	1,507	11,177	2,022	(471)
Reinsurers' share	(563)	(7,043)	(389)	454
Net premiums written	944	4,134	1,633	(18)
Gross premiums earned	1,323	8,623	1,686	7,793
Reinsurers' share	(531)	(5,225)	(365)	(1,851)
Net premiums earned	792	3,398	1,321	5,941
Gross claims incurred	118	(1,804)	(250)	(3,035)
Reinsurers' share	0	4	0	0
Net claims incurred	118	(1,800)	(250)	(3,035)
Net operating expenses	(1,005)	(3,589)	(547)	(618)
Other	10	44	17	77
Technical Result	(85)	(1,947)	541	2,365



# A.3.Investment Performance

The Company invests in rated and tradable Corporate and Government bonds.

The management of the bond portfolio is outsourced to another company within the wider international AmTrust group, which has a dedicated team of investment managers. A set of investment management guidelines has been drawn up by the Company, adherence to which is monitored by the Investment and Capital committee and the Audit, Risk and Compliance Committee, which are sub-committees of the Board. Income and expenses during the year are shown in the table below.

Corporate and Government Bonds	2018	2017
	£'000	£'000
Income from other investments	1,197	1,073
Investment management expenses	(134)	(78)
Realised gain/(loss) on sale of investments	(695)	364
	368	1,359

A.4. Performance of other activities

The Company did not undertake any other activities during the year.

A.5.Any other information

None noted.

# System of Governance


Section B



# B. System of Governance (unaudited)

B.1. General information on the system of governance

#### B.1.1. The Board and System of Governance



#### Note: INED - Independent Non-Executive Director

The Board and its sub-committees are shown in the diagram above. The Board closely monitors developments in corporate governance and assesses how these can be applied to AMIL. The Company's governance arrangements continue to be reviewed in line with developments in best practice. The Board believes the existing structure is appropriate for the size and complexity of AMIL. The Company follows the "Three Lines of Defence" model of corporate governance. In summary, the key differences between the lines of defence are as follows:

- First Line of Defence the primary risk taking and decision making activities take place here. It represents the bulk of the Company's people, systems and controls that are integral to achieving the Company's strategy;
- Second Line of Defence responsible for reviewing risks across the first line. No risk taking activities take place here. Key control functions such as Risk Management and Compliance reside here.
- Third Line of Defence the first and second lines together form the Company's system of governance and internal control. The Third Line is independent of first and second lines, and its primary objective is to provide assurance on the operation of the Company's governance and internal control systems. The Company relies on the Group Independent Internal Audit shared function which resides here.

The AMIL Board is collectively responsible for the long-term success of the Company and for compliance with all laws and regulations. Its role is to provide entrepreneurial leadership of the Company within a framework of prudent and effective controls which enables risk to be assessed and managed. The principal focus of the AMIL Board is on the overall policies, strategic plans, performance, annual budget, investment budgets, larger capital expenditure proposals and the Company's overall system of internal controls, governance and compliance. The Board develops and promotes its collective vision of the Company's purpose, its culture, its values and the behaviour it wishes to promote in conducting its business.



*The Board of Directors* consists of 6 members, including the Chairman of the Board as follows:

Board Member	Board Balance	Key Role
Chairman of The Board	Independent	Chairing the Board and the Remuneration Committee
Independent Non-Executive Director (INED)	Independent	Chairing the Audit, Risk and Compliance Committee
Non-Executive Director (NED)	Group Role	Shareholder Representative
Chief Executive Officer (CEO)	Executive	Day to day running of the Company
Chief Risk Officer (CRO)	Executive	Monitoring Risk Profile against appetite

Note: Chief financial Officer is not a member of the Board, but attends the board by invitation and chairs the Investment and Capital Committee.

Roles and responsibilities of the committees most relevant for Risk Governance purposes are briefly described below:

- AMIL Board: the Board is the main decision making body for the Company. It determines the overall strategic direction of the Company and has responsibility for its overall management, ensuring that proper financial reporting, risk management and corporate governance practices are in place. Formal Board meetings are held at least four times a year but calls, normally held monthly with the Non-Executive Directors are held as appropriate.
- Audit, Risk and Compliance Committee ("ARCC"): this Committee is to assist the Board of AMIL in discharging its responsibilities for the oversight, reporting, risk management and controllership matters of AMIL. Meetings shall be held no less than 4 times a year at appropriate times in the reporting and audit cycle, but calls with the Committee Members are held when necessary.
- Investment Committee ("IC"): this Committee is to establish strategic frameworks for the management of the assets of the Company and its segments, and to supervise the day to day stewardship of these assets by its appointed internal and external investment managers. IC reports to the Board.
- Risk Committee ("RC"): this Committee is responsible for all deal/product pricing approvals, policy and exposure limits for new products/countries and changes to existing commercial arrangements. It also covers the in-force reviews of the existing business (including operational risk and lenders' audit reviews), meaning all key underwriting decisions, contract modifications and approvals are centralised.
- Internal Model Steering Committee ("IMSC"): this quarterly Committee is responsible for independent oversight and challenge of key internal models (capital requirements, reserving and pricing). IMSC reports to the RC.
- **Remuneration Committee**: this Committee is responsible to define and update the Remuneration Policy of AMIL.

#### B.1.2. Changes in the System of Governance

During the year, there were no material changes in the system of governance.

#### B.1.3. Remuneration Policy

The Remuneration Policy describes the overarching principles and framework for the employees that fall within the scope of the Remuneration Policy. The Remuneration Policy is designed to support the appropriate management of employee compensation and act as reference for the Remuneration Committee, Board and Management when making decisions on pay. The Remuneration Policy and the associated remuneration plans and programmes will be regularly reviewed to ensure that they remain fit for purpose in terms of business strategy and applicable regulations.



#### B.1.3.1. Key Principles:

- Provide market competitive pay, typically aimed at market median for the business sector, role and location of the relevant employees; Individual pay rates may fall above or below market median based upon experience, tenure and performance in role as well as the market supply and demand for a particular skill set;
- Enable the Company to attract and retain the right talent for the business at an appropriate and sustainable cost;
- Provide pay structures which include a level of variable pay in line with market norms and an appropriate benefits programme;
- Ensure that pay programmes are aligned to the Company's business strategy, risk appetite statements, codes of conduct and applicable regulations and reward behaviour that is aligned to them. Ensure that both short and long term performance is taken into consideration.
- Ensure appropriate governance, independence and scrutiny over pay decisions relating to key employees including those designated as Solvency II employees.

#### B.1.3.2. Variable Pay

- Variable pay and the associated programmes and awards are structured according to the nature of the role and its position within the business.
- Fixed and variable pay are broadly aligned to market norms, with a sufficiently high proportion of pay delivered in fixed form to be competitive with market median levels and appropriate on a role-by-role basis.
- The proportion of pay delivered through variable remuneration generally increases with seniority within the organisation. This reflects the increased ability to impact the success of the organisation with increased seniority, and is in line with general market practice.
- Variable pay awards are designed to take into consideration both individual and company performance as appropriate for the role. Individual performance is assessed based upon performance against objectives (financial and non-financial) and also in line with the Company's competency framework. Company performance is aligned to agreed financial metrics.
- All variable pay programmes allow for no awards to be made based upon either individual and / or company performance.
- All programmes allow flexibility and discretion which permit the Board, Remuneration Committee and management to ensure appropriate awards are made in all circumstances.
- To ensure that the Company's senior employees (including the Company's Solvency II Employees) are aligned not only to the annual goals of the Company but equally as importantly, the long term success of the business and group, a substantial portion (50%) of any variable pay award in excess of a set threshold, is in the form of Restricted Stock Unit (RSU) awards which vest in equal amounts over a four year vesting period following grant.
- To ensure alignment to risk and performance of the business, provisions exist so that Remuneration Committee has the ability not to permit vesting of some or all of a tranche of the award.

#### B.1.3.3. Supplementary pension scheme for Board members

Board members who are also employees of the Company, that is all except Independent Non-Executives, are entitled to join a workplace pension scheme. The Company does not provide any supplementary pension to its Independent Non-Executives.

The Company provides a workplace pension scheme where all eligible members are automatically enrolled into the scheme and non-eligible or entitled workers can opt in to join the scheme. The pension scheme is a Group Flexible Retirement Plan which is designed to give members flexible ways to save for retirement. Both the employer and employee pay in a contribution which at the least meet the minimum legislative amount. The scheme has a default fund set up so members funds will automatically be invested in the default fund unless they actively choose their own investment funds.



There is only one Supplementary Executive Retirement Plan (SERP) applicable to one executive within the Company, the CEO & President. This is a bespoke defined and deferred benefit plan. The benefits relating to this supplementary plan were frozen as at June 2017.

#### B.1.4. Material transactions with shareholders, persons with significant influence and Board members

AMIL has had no material transactions with shareholders, persons with significant influence nor members of Board during the reporting period, save for the sale transaction mentioned in section A 1.7.

#### B.2. Fit and Proper Requirements

The PRA and FCA expect that individuals performing Senior Insurance Management Function (SIMF) or Controlled Function (CF) roles remain fit and proper to undertake the role. AMIL has a Fit and Proper Policy in place that outlines the various checks at recruitment and throughout employment. In particular, when deciding whether a person is fit and proper, AMIL satisfies itself that the individual:

- Has the personal characteristics (including being of good repute and integrity);
- Possesses the level of competence, knowledge and experience;
- Has the qualifications to undertake the role; and
- Has undergone or is undergoing all training required to enable such person to perform his or her key function effectively and in accordance with any relevant regulatory requirements, including those under the regulatory system, and to enable sound and prudent management of AMIL.

When deciding whether the Board is fit and proper, the Company seeks to ensure that the Directors collectively possess appropriate qualifications, experience and knowledge about at least:

- Insurance and financial markets;
- Business strategy and business model;
- Systems of governance;
- Financial and actuarial analysis; and
- Regulatory framework and requirements.

Fitness and propriety is checked at recruitment stage through appropriate due diligence and challenge of an individual's CV. Appropriate financial and criminal checks are carried out prior to recruitment of an individual and probation periods are set commensurate with the role. Ongoing assessment of fitness and propriety of all employees is assessed through the annual appraisal process. Performance of the Board is also assessed annually through the Board performance review process.

#### B.3. Risk management system including the own risk solvency assessment

#### B.3.1. Risk Management Strategy

Managing risk is central to AMIL activity and risk culture is embedded in the business through an organizational model where all members of the staff are accountable for different phases of the risk management process.

The Risk Department owns the Enterprise Risk Management process ("ERM") on behalf of the Board.

The diagram below shows the main components of the ERM process.



# **Risk Management Framework**

ANNUAL	QUARTERLY	MONTHLY	BAU
<ul> <li>MYP <ul> <li>Macroeconomics</li> <li>Loss Forecasting</li> <li>Stress Testing</li> </ul> </li> <li>Risk Governance <ul> <li>Risk Appetite</li> <li>Risk Policies</li> <li>Terms of Reference</li> <li>Risk Register</li> </ul> </li> <li>Risk Assessment</li> <li>Reinsurance Strategy</li> <li>Risk Governance <ul> <li>In-Force Review</li> </ul> </li> <li>ORSA</li> <li>Strategic Planning &amp; Budgeting</li> </ul>	<ul> <li>MYP - Review</li> <li>Capital Model</li> <li>Reserving Study</li> <li>Reinsurance Pack</li> <li>Risk Governance <ul> <li>ARCC &amp; Board</li> <li>Quarterly RADAR</li> <li>ERM Review</li> </ul> </li> <li>Controls Review and Monitoring</li> <li>Audit programme</li> </ul>	<ul> <li>Risk Reporting <ul> <li>Monthly Risk Pack</li> <li>Global Risk Report</li> </ul> </li> <li>Risk Governance <ul> <li>Monthly Extended RCC</li> </ul> </li> <li>Risk Register update (emerging risks)</li> <li>Loss &amp; Near Miss Report</li> <li>Financial Planning &amp; Analysis <ul> <li>Board Report</li> </ul> </li> <li>Capital Management</li> </ul>	<ul> <li>Pricing</li> <li>In-force Analysis</li> <li>Risk Governance <ul> <li>Weekly RCC</li> </ul> </li> <li>Data management</li> <li>Underwriting</li> <li>Claims management</li> <li>Loss Mitigation</li> <li>Controllership</li> <li>Investments</li> <li>Solvency II programme</li> </ul>

AMIL's overall approach to dealing with risk can be defined as follows:

- Assignment of authority, responsibility and accountability for risk areas within the firm.
- Identification of the key risks that exist within these areas.
- Measurement of risks by assessing the pertinence to the firm, stress and scenario testing of insurance risk financial forecasts and understanding the risk information and risk measurement techniques; and
- Monitoring risks through mechanisms such as risk assessments, compliance reviews, risk and investment committees, internal or external audits and escalation processes.

The above framework is clearly described in a set of Risk Policies (Insurance, Market, Liquidity and Operational Risk) approved and reviewed annually by the Risk Committee ("RC") and the Board. Additionally, a Capital Management Policy sets out the principles for managing economic and regulatory capital within AMIL. Stress Testing and ORSA Policies are also in place to ensure proper governance around these processes.

The Risk Appetite Statement ('RAS') approved by the Board offsets out the Company's appetite for risk over the medium term. The Statement also includes any additional limits set by the Parent company. The RAS assists and guides Senior Management and Staff in their day-to-day decision making and execution the strategic priorities.

The RAS is supported by the Company's ERM Framework designed to ensure the Company's risks are managed within its stated Risk Appetite.

The RAS focusses on three areas of our risk appetite.

- 1. Principles: guiding principles that are universal across all AmTrust businesses.
- 2. Financial metrics: key financial limits and tolerances
- 3. RAS by Risk Category: risk appetite, limits and tolerances by risk category.

The first section (Principles) sets out general qualitative criteria on risk appetite. The second section (Financial metrics) defines limits, tolerances and objectives for a set of quantitative indicators related to Capital, Return, Liquidity, Operational and Reputational Risks. The third part (RAS by Risk Category) includes simple/clear qualitative statements and references to quantitative metrics for each risk.

Risks are reviewed and re-assessed through the AMIL's Risk Assessment process which is briefly summarised below.




AMIL maintains a Risk Register where all financial and non-financial risks are fully described (including causes and consequences) and assigned to a Risk Owner. Additionally, all risks are associated to a set of controls (each of them owned by a Controls Owner).

An internal ERM tool is used within AMIL to monitor, control and report the Company's risks.

- On an annual basis the Company performs a Risk Assessment where all risks are reviewed and assessed on a gross and on a net basis (i.e. before/after controls).
- Risk owners assess the frequency and severity of each risk and the results are then discussed and challenged by the RCC which approves the final version of the Annual Risk Assessment.
- All risks are then monitored on a monthly/quarterly basis and any significant change in frequency and/or severity is reported to the RCC and to the ARCC/Board. This includes any new emerging risk.
- The risk monitoring process consists of two separate stages: firstly, Controls Owners are asked to perform a self-attestation process of their controls. The assessment is reviewed and challenged by the Risk Governance team on behalf of the CRO.

The consistency of the above "Bottom-Up" approach with the Senior Management assessment ("Top-Down" approach) of the risks associated to the strategy is periodically re-assessed to ensure that the ERM Framework remains aligned to the company's strategy and risk appetite.

#### B.3.2. Own Risk and Solvency Assessment (ORSA)



The above diagram shows how the various aspects of risk management, capital management, and regulatory reporting under Solvency II fits together for AMIL.

The Own Risk and Solvency Assessment (ORSA) forms a key part of ERM at AMIL and is performed at least annually. It is the process through which the Board and Management team assess the risks faced by AMIL, both now and in the future, and the level of own funds that are necessary to meet the strategic goals of the Company. Therefore, ORSA is termed to be an Economic assessment of capital.

Economic Capital differs from Regulatory Capital. The latter is the Regulator's assessment of AMIL's capital required to continue and meet the Regulator's objectives, which includes maintaining safety and soundness in the wider financial system. AMIL's solvency risk appetite is that capital should always remain above a margin of these limits and has set this to be 120% of the SCR (the Regulatory Capital requirement under Solvency II).



ORSA places in context the Company's historic and prospective strategy and what risks this creates for the Company's Economic balance sheet both now and in the future. Economic Capital should then be held at a level that allows AMIL to achieve this strategy and manage these risks.

The Company's balance sheet is managed through the Internal Economic Capital Model and a key metric agreed with the PRA to constantly re-assess the Standard Formula appropriateness is the difference between SCR and the internal assessment of the Economic Capital (the two should remain within a +/- 10% range).

AMIL completes the ORSA process annually, or more frequently if there is a material change in the risk profile.

#### B.4. Internal control system

#### B.4.1. Internal Control system

The Internal Control System refers to the existence and operation of all the detailed controls that are integrated into the daily operating routines of the business.

A comprehensive system of internal controls is in place in AMIL. The controls are either performed automatically (for example computer validation routines) or manually (for example financial reconciliations.

The role of internal controls in effective risk management is critical. The quarterly risk assessment and controls reviews, described earlier, that are performed by risk owners. In making that assessment, the risk owners are in effect assessing whether the internal controls operating within their area are adequate in design and operating effectively.

As a further check, the Internal Audit function is responsible for auditing the control environment against the audit plan agreed by the Audit Committee.

#### B.4.2. Compliance function

The Compliance function is responsible for advising the Executive and the Board on compliance with existing and emerging legal, regulatory and administrative provisions.

The Compliance Function has the right to escalate to the Board, directly or through its Committees, any instances of non-compliance with this policy.

Compliance takes responsibility for identifying and assessing the wide ranging internal and external obligations the Company has. The Compliance function helps to ensure that AMIL clearly understands its regulatory risks and the prevailing requirements.

The compliance function undertakes checks to ensure that compliance obligations are being met after implementation through a systematic, disciplined and risk based approach to evaluating the effectiveness of compliance controls.

The compliance function is a shared service, which is housed in AMIL's direct parent company AEL.

#### B.5. Internal audit function

The mission of the AmTrust Internal Audit function is to help the Board and Executive Management to protect the assets, reputation and sustainability of the organisation.

This is achieved by:

- Assessing whether all significant risks are identified and appropriately reported by management and the Risk function to the Board and Executive Management;
- Assessing whether they are adequately controlled; and
- By challenging Executive Management to improve the effectiveness of governance, risk management and internal controls.

Internal Audit is independent from the business and is directly responsible to the Chairman of the Audit Committee, with a day-to-day administrative reporting line to the Group Chief Executive Officer of the AmTrust European Group of entities. Internal Audit shall have free and unrestricted access to the Chairman of the Board, the Chairman of the Audit Committee and the Chief Executive Officer.



Those working within Internal Audit are not permitted to perform day-to-day control procedures or take operational responsibility for any part of AmTrust's operations outside Internal Audit. Management is responsible for the establishment and ongoing operation of the internal control system. The Audit Committee reviews the scope and nature of the work performed by Internal Audit to confirm its independence.

The internal audit function is a shared service function, which is housed in AMIL's direct parent company AEL.

### B.6. Actuarial function

The purpose of the Actuarial department within group is to provide support to the Company in many areas including reserving, pricing and capital management. Additionally, other statistical and management information support is provided where necessary. This work is required to be undertaken in an objective and independent manner whilst incorporating feedback from the business where appropriate.

The Actuarial Function is a Key Function, the Chief Actuary being the Key Function holder. The Chief Actuary is a qualified actuary and a member for the Institute and Faulty of Actuaries and reports to the Chief Executive Officer of AmTrust International Limited, a group company. Other members of the team are either qualified actuaries; working towards becoming a qualified actuary; or sufficiently qualified by experience to undertake the duties assigned to the individual.

The Actuarial function has the following specific responsibilities:

- Production of the Technical Provisions in accordance with Solvency II principles and ensuring that methodologies and underlying models used are appropriate;
- Monitoring the best estimates against actual experience;
- Providing assistance for the pricing of insurance risks;
- Providing inputs into the calculation of the Solvency Capital Requirement ("SCR");
- Providing assistance for the preparation of business plans;
- Working closely with the Risk Management Function ("RMF") to facilitate the implementation of an effective risk management system;
- Assessing the data quality used in actuarial functions;
- Reporting to the Board on the reliability and adequacy of the Technical Provisions calculation;
- Reviewing reinsurance arrangements;
- Opining on the overall underwriting policy; and
- Opining on the adequacy of reinsurance arrangements.

#### B.7. Outsourcing

Outsourcing is an important aspect of the AMIL business model. The majority of AMIL's key outsourcing risk lies in its use of a service company, AMT Mortgage Services Ltd. (AMSL), as well as other group shared service functions.

Key outsourcing risk refers to those functions that are required by AMIL; either, from external; or, from intra-group providers which are essential to AMIL's operations, and that AMIL would, otherwise, be unable to deliver its services to policyholders without the outsourced function(s).

Key outsourced functions:

- Investment management and accounting (AmTrust group company Internal outsourcing)
- Staff and administration services (AMSL and AMTSL Internal outsourcing)
- Taxation (Internally and Externally outsourced)
- Application support services and IT development (Externally outsourced)

Prior to engaging with external outsourcing providers AMIL undertakes due diligence to ensure the supplier has the necessary infrastructure to supply the service. The financial stability and size of the organization are also considered to ensure that they will be in operation during the service period.

The PRA requires AMIL to take reasonable steps to avoid undue additional operational risk and not to undertake the outsourcing of key functions in such a way as to either: risk impairment of the firm's own internal control; or, risks associated with the PRA's ability in monitoring AMIL's compliance obligations under the regulatory system.

# **Risk Profile**

Section C



# C. Risk Profile (unaudited)

### C.1.Underwriting risk profile

Underwriting risk refers to fluctuations in the timing, frequency and severity of insured events, relative to the expectations of the firm at the time of underwriting.

The Company uses a suite of Key Risk Indicators (KRIs) to monitor its exposure to underwriting risk that are evaluated each month. These include: volume of premium underwritten; priced loss ratios in comparison with the Company's annual business plan; ultimate loss ratios in comparison with plan; concentration of premium and profit contribution by type of exposure; and deterioration in prior year reserves.

#### C.1.1. Material risk exposures

Capital allocated to underwriting risk represents 65% of the pre-diversification total Solvency Capital Requirement (SCR).

The Company is exposed to premium risk, that is, the risk that premiums are insufficient to cover the value of claims made; and reserve risk, the risk that on-going claims are settled at a higher value than previously expected. The majority of the Company's material underwriting risk exposure is in Italy. The SCR quantifies the potential for adverse development as part of the calculation of the premium risk and reserve risk calculation. Given the nature of the mortgage insurance business, an additional capital charge for catastrophe risk in included in the SCR.

#### C.1.2. Material risk concentrations

AMIL's underwriting risk exposure is concentrated in Italy. The company has purchased excess of loss insurance to mitigate this concentration

#### C.1.3. Material risk mitigation

The Actuarial Pricing team review new business to determine that rates are adequate. There is constant monitoring of underwriting performance by management, which allows corrective action to be taken if a piece of business is not performing as expected.

AMIL also uses reinsurance to mitigate underwriting risk. This takes the form of a 33.3% (renewed at 50% for origination year 2019) quota-share agreement for new business in Italy, Germany and UK and an excess-of-loss agreement for the exposure in Italy. There has not been any material changes to the measures used to assess exposure and material risks.

#### C.1.4. Risk sensitivities

AMIL has performed a series of sensitivity tests on its solvency position; these are shown in section C.7.1.

#### C.1.5. Other material information

None noted.

#### C.2.Market risk

Market risk is the risk of loss of income or decrease in the value of assets caused by movements in the level and prices of financial instruments. Market risk includes factors such as equity values, property values, interest rates, foreign exchange and spread risk.

The KRI process identifies and measures the key market risk exposures by monitoring the currency and duration mismatch to capture exposure to currency and interest rate risks, as well as the composition of the bond portfolio holdings by credit ratings to capture exposure to spread risk (i.e. credit risk of market instruments exposure). A currency split balance sheet is prepared to review the Company's asset liability matching, and the asset portfolios duration is reviewed in order to ensure these elements are no adding undue burden on the Company's capital requirements. Due to the current stable and low risk nature of the investment portfolio, this is reviewed as part of the ICC. Should the need arise for more regular reviews these will be implemented.

Investments are reviewed quarterly by the Investment Committee and the Audit, Risk and Compliance Committee.

#### C.2.1. Material risk exposures

Capital allocated to market risk represents 28% of the pre-diversification total SCR.



The Company's material exposures to market risk are: interest rate risk and spread risk on its bond portfolio; foreign exchange risk on its currency exposures; and equity risk on its strategic investments in subsidiaries. The bond portfolio consists of corporate and government bonds. It is exposed to interest rate risk, as well as to credit spread risk. Fluctuations in rates of inflation influence interest rates, which in turn impact the market value of the investment portfolio and yields on new investments. Thus, rising interest rates would have an adverse impact of the bond portfolio and would drive the value of the bonds down. Whereas, widening credit spreads would also negatively impact the value of the bond portfolio.

#### C.2.2. Material risk concentrations

AMIL's material market risk exposures are to its equity investment in AMSL, its foreign currency exposure to the Sterling and the exposure of its predominantly fixed rate corporate bond investment portfolio to spread risk.

#### C.2.3. Material risk mitigation

AMIL operates a conservative investment strategy, investing primarily in fixed rate corporate bonds, money market deposits and cash. The Company has no appetite for investments in equities (other than wholly-owned subsidiaries) and complex investments such as derivatives. By investing in relatively simple assets, the Company fulfils the Prudent person principle because it is able to properly understand its investment risks.

Investment management is outsourced to another company within the group. A set of investment management guidelines has been drawn up, adherence to which is monitored by the Investment Committee and the Audit, Risk and Compliance Committee.

AMIL monitors interest rate risk as part of its regulatory reporting process by monitoring duration of assets and liabilities. Any gap between the mean duration of the assets and the estimated mean duration of the liabilities is minimised by means of buying and selling fixed interest securities of different durations.

AMIL is exposed to foreign exchange risk, by operating in multiple currencies. AMIL seeks to mitigate the currency risk by matching the estimated foreign currency denominated liabilities with assets denominated in the same currency. AMIL's currency matching strategy is well protected against depreciation of Sterling. There has not been any material changes to the measures used to assess exposure and material risks.

#### C.2.4. Risk sensitivities

AMIL has performed a series of sensitivity tests on its solvency position; these are shown in section C.7.1.

#### C.2.5. Other material information

None noted.

#### C.3.Counterparty default risk

Counterparty default risk is the potential loss arising principally from adverse changes in the financial condition of AMIL's counterparties (reinsurers, intermediaries, policyholders, etc.)

The risk and management team identifies and measures the key credit risk exposure by monitoring the rating of each reinsure and capping the exposure to individual external reinsurer counterparty

Capital allocated to credit risk represents 5% of the pre-diversification total SCR.

#### C.3.1. Material risk exposures

AMIL is subject to material risk exposures with respect to its reinsurers.

#### C.3.2. Material risk concentrations

The Company is exposed to credit risk in relation to material accounts with our Reinsurance counterparties, as well as to concentration risk in the bond portfolio.

#### C.3.3. Material risk mitigation

In order to reduce our exposure to reinsurance credit risk, the financial condition of reinsurers is evaluated and reinsurance is placed with a diverse group of companies and syndicates that are believed to be financially sound. The credit quality of reinsurers is monitored when placing new and renewal reinsurance, as well as on an ongoing, current basis. AMIL uses objective criteria to select and retain its reinsurers, including requiring an adequate financial strength are also in place for certain counterparties as is deemed appropriate within the business.



The bond portfolio concentration is managed in line with the Company's investment guidelines which restrict investment to rated government and corporate bonds. Duration and rating thresholds are set in accordance with the Company's risk appetite. Formal reviews of the portfolio are quarterly within the ICC.

#### C.3.4. Risk sensitivities

AMIL has performed a series of sensitivity tests on its solvency position; these are shown in section C.7.1.

#### C.3.5. Other material information

The Company benefits from a guarantee from its indirect parent company, **AmTrust North America (ANA)**, an **enterprise registered and incorporated in Bermuda**. This guarantee covers up to €40MM of adverse development on technical reserves. The yearend rating of AII is A- as rated by AM Best.

#### C.4.Liquidity risk

Liquidity risk represents the Company's potential inability to meet all payment obligations when they become due and the risk stemming from the lack of marketability of an investment security that cannot be bought or sold quickly enough to realise cash.

The finance team carries out regular cash-flow forecasting and analysis to monitor the Company's liquidity needs. Operational cash outflows are funded through operational cash flows inward. Infrequent "one off" payments such as lender settlements are planned in line with investment maturities in the annual, quarterly and monthly cash flow forecasting process.

The Company recognises that EPIFP can contribute to an increase in future net cash flows and therefore can act to reduce liquidity risk. EPIFP is the expected present value of the future cash-flows of legally obligated unincepted and incepted insurance contracts. This value forms part of the calculation of Solvency II technical provisions. The EPIFP as at 31 December 2018 is £1,760,000. The calculation of the EPIFP has been performed to understand the level of expected profit within premiums that are expected to be received in the future. This calculation has inherent uncertainty as it is on a planning basis and actual outcome may differ materially.

#### C.4.1. Material risk exposures

There are no material risk exposures to liquidity risk, as the all of the Company' assets are invested in highly liquid corporate and government bonds.

#### C.4.2. Material risk concentrations

AMIL's liquidity risk exposure is concentrated in reinsurance contracts, financial assets (bonds) and cash.

#### C.4.3. Material risk mitigation

The Company's overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effect on AMIL's financial performance. It manages these positions within an asset liability management (ALM) framework that has been developed to minimize the risk of significant deterioration of the investment portfolio while earning profitable returns from those investments.

The Company invests mainly in corporate bonds, which are normally readily convertible into cash, so it holds relatively small amounts of cash. It accepts the risk that during times of stress, there may be market value losses realised by liquidating bonds.

AMIL maintains sufficient cash and highly rated marketable securities, to fund claim payments and operations. There has not been any material changes to the measures used to assess exposure and material risks.

The Company recognises that EPIFP can contribute to an increase in future net cash flows and therefore can act to reduce liquidity risk. EPIFP is the expected present value of the future cash-flows of legally obligated incepted and unincepted insurance contracts. This value forms part of the calculation of Solvency II technical provisions.

The EPIFP as at 31 December 2018 is £1,760,000. The calculation of the EPIFP has been performed to understand the level of expected profit within premiums that are expected to be received in the future. This calculation has inherent uncertainty as it is on a planning basis and actual outcome may differ materially.



#### C.4.4. Risk sensitivities

Unless there is a default in collecting reinsurance receivables due to adverse market conditions, the Company has no significant impact to its liquidity. This is mitigated by AMIL using an external panel of quota share reinsurers, rather than a single counterparty.

#### C.4.5. Other material information

None noted.

#### C.5.Operational risk

Capital allocated to operational risk represents 3% of the pre-diversification total SCR.

Operational risk is the risk that the Company will not be able to operate in a fashion whereby the strategic objectives of the Company can be met due to inadequate or failed internal processes, people and systems, or from external events. It arises out of actions undertaken within the Company, clients, investment management companies or outsourced agencies and individuals.

AMIL has risk management processes in place, such as lenders ´ audit, internal audit, controls testing, project management, Risk and Control Self-Assessment (RCSA), data governance management to assess and monitor operational risk exposures.

#### C.5.1. Material risk exposures

The Company is exposed to IT, Data, Outsourcing, Underwriting, Reinsurance, Fraud, Legal, and Reputation risks.

A critical operation risk is the Company's ability to effectively monitor how lenders' underwrite their mortgages under the "Delegation of Authority" model. This is managed through periodical review of portfolios performance and composition as well as through regular audits.

#### C.5.2. Material risk concentrations

None.

#### C.5.3. Material risk mitigation

AMIL does not seek to take on operational risk in order to generate a return. However, it recognises that some degree of operational risk is an unavoidable consequence of remaining in business. It therefore seeks to mitigate this risk through its corporate governance and internal control mechanisms, peer view, due diligence and business continuity.

All of AMIL's operational risks are captured within the Company's risk register. Risk Management carry out a risk and control self-assessment exercise where meetings are held with each key risk owner to review and update the risk registers with new risks and controls, as well as judging whether the ratings for inherent and residual risks are still valid.

#### C.5.4. Risk sensitivities

AMIL has performed a series of sensitivity tests on its solvency position; these are shown in section C.7.1.

#### C.5.5. Other material information

None noted.

#### C.6.Other material risks

#### C.6.1. Legal and Regulatory risks

The risk of non-compliance with regulation and legislation.

AMIL does not seek to take on legal and regulatory risk in order to generate a return. However, it recognises that some degree of legal and regulatory risk is an unavoidable consequence of remaining in business. It therefore seeks to mitigate this risk through its corporate governance and internal control mechanisms. Awareness of the risks and the Company's control mechanisms are maintained through its policies & procedures framework and training programmes.



#### C.6.2. Strategic risk

Risks arising from failure to sufficiently define the direction and objectives of the entity, together with the resourcing and monitoring of the achievement of the same.

AMIL has a well-developed business planning process and its business plans are approved by the Board. The business plans are also used in the Own Risk and Solvency Assessment (ORSA) process.

#### C.6.3. Governance risk

Risks arising from the failure to demonstrate independent and proper stewardship of the affairs of the entity in order to safeguard the assets of the entity's shareholders and the overall interests of its stakeholders.

The Company regards a strong Governance framework to be vital in the achieving its objectives as well as providing transparency and accountability to its various stakeholders. A system of internal control and governance has been developed using the "three lines of defence" model.

#### C.6.4. Group risk

The risks arising from other parts of its group, through parental influence or direct contagion.

AMIL maintains a good relationship with its ultimate parent and expects that, at all times, it will remain suitably apprised of all of the material risks within the group that may, if crystallised, have negative impact upon the business strategy and/or cause detriment to its customers.

Regular meetings with AFSI Group Risk department. The AFSI Group CEO also holds approved person status under the Senior Insurance Managers Regime (SIMR).

Although AMIL is part of the wider AmTrust Group, it is a separate regulated entity under the UK PRA and is managed accordingly in terms of capital adequacy, risk management, governance, compliance and infrastructure.

#### C.6.5. Solvency risk

The risk that the entity fails to maintain adequate levels of capital resources of sufficient quality and quantity in order to carry out its business objectives and in order to meet all domestic and international regulatory considerations regarding the capital resource requirements.

AMIL ensures it is solvent at all times through: Monitoring of solvency position; Management Accounts; Solvency forecasting in ORSA and prior to any strategic decision making.

#### C.6.6. Reputational risk

The risk relates to potential losses resulting from damages to the Company's reputation, which could be manifested in terms of lost revenue; increased operating, capital or regulatory costs; or destruction of shareholder value.

AMIL manages reputational risk by operating to high standards across its business activities, and continuously monitoring feedback from its key stakeholders, including customers and regulators.

#### C.7.Any other information

#### C.7.1. Risk sensitivities

AMIL has performed sensitivity tests to show the impact on SCR and solvency coverage by changing the assumptions associated with each risk type in the SCR calculation. These are independent stresses to individual risks, although in practice risks may occur in combination, but the impact would differ from the combination of impacts of the individual stresses. No future management actions, which could mitigate the impacts shown, have been taken into account. The impacts of each stress are non-linear and the results shown should not be used to extrapolate the effects of larger or smaller changes in the assumptions.



Risk category	Test	SCR (£m)	Change in SCR (£m)	Change in Solvency ratio (%)
Underwriting	25% increase in volume of GWP in next 12 months	39.5	0.1	(0.8)%
Underwriting	25% decrease in volume of GWP in next 12 months	39.3	(0.1)	0.8%
Underwriting	25% increase in Claims provisions	42.9	3.4	(34.0)%
Underwriting	25% decrease in Claims provisions	36.2	(3.2)	39.0%
Market	25% increase in asset durations	40.9	1.4	(7.5)%
Market	25% decrease in asset durations	37.9	(1.5)	8.4%
Market	10% of investment portfolio moved to the two most concentrated exposures	39.6	0.1	(0.8)%
Market	10% increase in currency exposure for each currency	37.5	(1.9)	11.1%
Market	10% decrease in currency exposure for each currency	41.8	2.4	(12.3)%
Credit	Fall in rating of one credit step for three largest insurers	40.5	1.1	(5.7)%
Credit	Fall in rating of one credit quality step for securitisation positions held	39.4	-	0.0%
Credit	Double the proportion of debtors overdue by more than 3 months	39.5	0.1	(0.3)%
Operational	Increase in technical provisions of 25%	43.0	3.6	(45.3)%

AMIL has performed the following sensitivity tests on its solvency position.

# Valuation for Solvency Purposes

Section D



# D. Valuation for solvency purposes

#### D.1. Assets

As a general principle, AMIL's assets and liabilities are valued differently when calculating its own funds under Solvency II and when preparing its annual accounts for filing at Companies House. The former applies the valuation rules from the Solvency II Directive, and the latter applies valuation rules under Generally Accepted Accounting Principles (GAAP) in the UK.

	31.12.2018	31.12.2018	
Category	Solvency II	UK GAAP	Difference
	(£'000)	(£'000)	
Deferred Acquisition Costs	0	2103	(2,103)
Property, plant & equipment held for own use	19	19	0
Holdings in related undertakings, including participations	3,989	3,158	831
Investment Bonds	120,812	119,958	854
Collective Investments Undertakings	87	86	1
Reinsurance recoverables	3,741	15,062	(11,321)
Insurance and intermediaries receivables	1,708	7,074	(5,366)
Reinsurance receivables	467	3,254	(2,787)
Receivables (trade, not insurance)	55	55	0
Cash and cash equivalents	4,099	4,097	(3)
Any other assets, not elsewhere shown	0	812	(812)
TOTAL ASSETS	134,972	155,678	(20,706)
Technical provisions - non-life (excluding health)	46,486	65,467	(18,981)
Reinsurance payables	1,763	6,430	(4,667)
Payables (trade, not insurance)	11,634	11,634	0
TOTAL LIABILITIES	59,883	83,531	(23,648)
Excess of Assets over Liabilities	75,089	72,147	2,942

This section highlights the way AMIL values its assets and liabilities using the Solvency II valuation principles and, where relevant, explains any material differences to the UK GAAP valuation approach followed in its last reported financial statements.

#### D.1.1. Deferred acquisition costs

Deferred acquisition costs are costs relating to contracts in force at the balance sheet date which are carried forward to subsequent periods, in relation to unexpired periods of risk. In accordance with Article 12 of the Solvency II Delegated Acts, deferred acquisition costs are valued at zero under Solvency II.

#### D.1.2. Property plant and equipment held for own use

Under Solvency II the valuation of property, plant and equipment should be a reliable estimate for the amount which the assets could be exchanged between knowledgeable willing parties in an arm's length transaction.

Less than £0.1m is held within plant and equipment and, as a result, management do not believe that using depreciated cost would generate a materially incorrect position against the market value.

#### D.1.3. Investments (other than assets held for index-linked and unit-linked contracts)

AMIL has an investment portfolio made up of corporate and government bonds.



The Company elects to carry its investments at fair value. The UK GAAP accounting designation is "available for sale", which takes fair value adjustments through equity. These assets are managed and their performance evaluated on a fair value basis.

The fair values of these financial instruments are based on quoted prices as at the balance sheet date.

According to the valuation rules contained within Article 75 of Directive 2009/138/EC this method can be consistently applied under SII and therefore no adjustments are made to the UK GAAP position.

#### D.1.4. Investments in subsidiaries and participations

In accordance with Delegated Regulation (EU) 2015/35 Article 13, AMIL is valuing its holdings in related undertakings, in accordance with the following order of hierarchy:

- Valued based on quoted prices in active markets where available.
- Where quoted prices in active markets are not available, valued on an adjusted equity method (based on Solvency II valuation of underlying net assets or, for related undertakings other than insurers where this is not practicable, based on IFRS with the deduction of goodwill and intangibles).
- For related undertakings other than subsidiaries, where quoted prices in active markets are not available and where it is not possible to apply an adjusted equity method, an alternative valuation method (e.g. mark to model) may be used.

As AMIL's only related undertaking AMSL is not listed, it is valued on the adjusted equity method.

AMSL is a subsidiary other than an insurance entity, hence the adjusted equity method means using the excess of assets over liabilities using International Accounting Standards excluding any value in goodwill or intangibles (Article 13(5)). For this purpose, the entity has assumed the UK GAAP position is a reasonable approximation for the fair value reflected by the entities underlying assets and liabilities.

As equity holdings, the investments attract equity and concentration risk charges as appropriate.

Category	UK GAAP	Reclassification	Valuation	Solvency II
(£'000)		Adjustment	Adjustment	
Corporate Bonds	117,704	854	-	118,558
Government Bonds	2,253	1		2,254
Participations	3,158	-	831	3,989

Accrued interest on bonds is shown in the combined bond value under Solvency II, rather than separately on the face of the balance sheet as with UK GAAP.

Investment in subsidiary (participation) is shown using the adjusted equity method under Solvency II versus historic cost under UK GAAP.

#### D.1.5. Reinsurance Recoverable

Refer section D.2 below, Technical provisions.

#### D.1.6. Insurance debtors and creditors

Insurance debtors and creditors are held are held at amortised cost under UK GAAP, due to the short term nature of these payables this does not differ materially from their fair value and hence is considered appropriate.

An adjustment is made to these balances for the impact of future premiums (including commissions and reinsurance as appropriate). Future premiums relate to the future collection or payment of cash relating to premiums and commissions which are dealt with as part of the wider technical provision calculation.

Category	UK GAAP	Reclassification	Valuation	Solvency II
(£'000)		Adjustment	Adjustment	
Insurance and intermediaries receivables	7,074	-	(5,366)	1,708



#### D.1.7. Reinsurance receivables

Reinsurance receivables relate to reinsurance profit commission receivable, based on the underlying performance of the insurance business under an earned premium, UK GAAP approach.

An adjustment is made to this balance under Solvency recalculating the receivable based on future discounted cash flows.

Category	UK GAAP	Reclassification	Valuation	Solvency II
(£'000)		Adjustment	Adjustment	
Reinsurance receivables	3,254	-	(2,787)	467

#### D.1.8. Receivables (trade, not insurance)

All other debtors and creditors are held are held at amortised cost under UK GAAP, due to the short term nature of these payables this does not differ materially from their fair value and hence is considered appropriate.

At present no further adjustments are made to the UK GAAP balance sheet to move to Solvency II.

Due to the company's large carry forward tax losses, and loss making experience between 2008 – 2015, no deferred tax assets have been recognised in accordance with IAS12 accounting principles.

#### D.1.9. Cash and cash equivalents

Cash and cash equivalents comprise cash with banks, and are considered to be held at fair value under Solvency II.

#### D.1.10. Any other assets, not elsewhere shown

This relates to accrued interest on bonds, refer section D1.3.

#### D.2. Technical Provisions

On a Solvency II basis, the total net Technical Provisions (TPs), including the Risk Margin, were £46.4m compared to £65.5m on a statutory basis. The TPs are the best liabilities and risk margin. As the Company is a mono line insurer the below table relates to its only line of business, credit and suretyship.

Technical Provisions	£m	
Gross Best Estimate		
Claims Provisions	25.9	
Premium Provisions	16.6	
Risk Margin	4.0	
Gross Technical Provisions	46.5	
Net Best Estimate		
Claims Provisions	25.6	
Premium Provisions	16.8	
Risk Margin	4.0	
Net Technical Provisions	46.4	

#### D.2.1. Methodology and main assumptions

AMIL's Actuarial Function calculates the Technical Provisions, considering the following elements:

- Claims projections.
- Expense projections.



- Premium in-flows and out-flows.
- Reinsurance recoveries.
- Risk margin.

# D.2.1.1. Claims projections

AMIL's Actuarial Function calculates claims projection using the outputs from our stochastic Economic Capital Model. The capital model projects claims to ultimate over a range of economic scenarios. The best-estimate for insurance claims is the stochastic mean of the cashflow projections, allocated to claims from incurred events (Claims Provisions) and claims from future events (Premium Provisions). These cashflows are then discounted using risk-free yield curves.

# D.2.1.2. Expense projections

AMIL's Actuarial Function projects the expenses attributable to the in-force business at the valuation date (including Bound-But-Not-Incepted, or BBNI, business). It takes the projections of the total future expenses for the legal entity from our annual business planning exercise and then allocate these expenses to the in-force business at the valuation date, using a driver-based expense analysis and projections of the underlying drivers. Finally, these expenses are then discounted using risk-free yield curves.

# D.2.1.3. Premium in-flows and out-flows

The majority of our business in single up-front premium, except for our German and Swedish business which are paid annually and quarterly respectively.

We project the future premium for this business using standard lapse and amortisation assumptions used elsewhere throughout the business.

Additionally, we allow for the expected future premium received for the BBNI business assumed.

Finally, we have a 33% quota share arrangement on all business written since 2011 till 2018 and this cession is increased to 50% for business written in 2019 driven by the AmTrust's strategy of protecting its longer tail risk. For this business, we allow for the reinsurance premium payable to the reinsurers in calculating the Net TPs.

#### D.2.1.4. Reinsurance recoveries

Our reinsurance program comprises the aforementioned quota share reinsurance, and one aggregate excess-of-loss (XoL) treaty on our Italian business.

We calculate the reinsurance recoveries using our Economic Capital Model. The quota share recoveries are a simple proportion of the claims form our 2011 & 2018 business. The XoL recoveries will apply to some individual stochastic scenarios, and the overall recovery is the stochastic mean across the whole range of scenarios.

The recoveries are discounted using risk-free yield curves.

# D.2.1.5. Risk Margin

We have opted to use a fixed percentage of Net Claims and Premium Provision for our Risk Margin. The fixed percentage is 9.5%, which was recommended for Credit and Surety business in the QIS exercises prior to the final agreement of the Technical Specifications.

# D.2.2. Uncertainty in Technical Provisions

The uncertainty in the value of the Technical Provisions arises from three main areas:

- Future performance of the in-force business.
- Expenses of the legal entity.
- Future revenue streams.



## D.2.2.1. Future performance of the in-force business

#### D.2.2.1.1 Economics

The Economic Capital Model uses an economic scenario generator which produces stochastic economic forecasts around a deterministic forecast in each of our territories. This deterministic base case is uncertain to varying degrees in each country, with several factors giving rise to significant uncertainty in the European economic outlook, e.g. Brexit, upcoming elections, etc.

#### D.2.2.1.2 Settlement activity

We actively pursue settlements with many of our clients, either on tranches of highly delinquent loans for our larger lenders (partial settlements) or full commutations with our smaller lenders in runoff. The amount of these settlements can vary from the value of reserves in the TPs, which creates uncertainty in the ultimate cashflows relating to these parts of the business.

### D.2.2.1.3 Model risk

Parts of our overall portfolio are subject to a higher degree of model risk, e.g. the countries with lower volumes of performance data (Germany, Portugal, Spain, Sweden), and our younger books which have less development and therefore rely on benchmarking to prior years.

The first example of small data volume in specific countries is self-mitigating to a degree – the lower the volume of data, the less material to the overall value of TPs.

The second example accounts for more uncertainty, although our underwriting standards have been consistent for several years now since late 2009 onwards which would lead us to expect consistent performance relative to the economic outlook.

### D.2.2.1.4 Ireland runoff

The Irish central bank introduced their Mortgage Arrears Resolution Process ("MARP") in 2013, which sets out rules for lenders to deal with their non-performing loan portfolios. The main impact was to force lenders to implement long-term sustainable workout solutions for delinquent loans, rather than "kicking the can" down the road.

At around the same time, we entered a settlement agreement with our sole remaining lender in Ireland which clearly specifies the circumstances that lead to a claim event, and the quantum of that claim. This has reduced the inherent uncertainty in the level of reserves we need to hold for Ireland.

# D.2.2.2. Expense of the legal entity

AMIL has taken several expense actions over recent years, and has also moved to a new parent which has taken over the provision of certain shared services. This has lowered our expense base considerably, but also leads to uncertainty over the company's future operating expenses – for solvency purposes, we have adopted a conservative view of expenses in calculating the TPs at year end 2018.

# D.2.2.3. Future revenue streams

Future revenue comes from two sources:

- Regular premium business in Germany and Sweden uncertainty arises from future lapse rates and amortisation of the loans.
- BBNI business on a short term timeframe (up to six months, varying by lender), volumes can be volatile, creating uncertainty in the TPs.


#### D.2.3. Differences between Solvency II valuation and financial statements

Solvency II Technical Provisions are set according to very different principles to UK GAAP Technical Provisions.

The chart and table below shows the impact of the differences in the bases, methods and assumptions between the two regimes.



AMIL – GAAP to Technical Provisions (£m)



Note: The above waterfall chart walks the UK GAAP gross technical provisions to Solvency II net technical provisions.



# D.2.3.1. Margin for prudence and reinsurer bad debt

We do not hold any margin for prudence or provisions for reinsurer bad debt in our UK GAAP reserves. Our counterparties are all highly rated and we do not feel any such margin is appropriate

## D.2.3.2. UPR

Under Solvency II, the UPR has been replaced by the Premium Provisions.

The UPR consists of future incurred claims, future expenses and future profits.

The Premium Provisions contain the best estimate for future incurred claims and expenses, less future premiums receivable, i.e. profits are recognised on inception of the insurance business.

#### D.2.3.3. Deferred acquisition costs

Under Solvency II, there is no allowance for Deferred acquisition costs.

#### D.2.3.4. Future premiums – incepted contracts

Under Solvency II, the Premium Provisions allow for future premium receivable. This item related to the premium from our regular premium business in Germany and Sweden – the rest of our business receives single upfront premium.

#### D.2.3.5. Future premiums - unincepted contracts

Under Solvency II, you need to reserve for business you have committed to write in the future, not just business that has already incepted.

Most of our policies contain a cancellation period of between three and six months, during which time we are obliged to accept new business.

#### D.2.3.6. Net premium provision – claims component only

We calculate the best estimate for future incurred claims using our Economic Capital Model, as described above in section D.2.1.1. For this item, we use the deterministic loss forecast from our base case economic scenario – see section D.2.3.8 below for further explanation.

#### D.2.3.7. Additional expenses

Under UK GAAP, the expenses for the in-force business are the loss adjustment expenses ("LAE") in the loss reserves and the expenses part of the UPR.

Under Solvency II we project expenses as described above in section D.2.1.2.

Therefore, this additional expenses item is the total Solvency II expenses less LAE (UPR having already been removed in a previous step).

## D.2.3.8. Events not in data

Under Solvency II, we are required to calculate the best estimate, defined as the probability-weighted average of future cashflows, taking account of the time value of money.

Many firms have adopted an approach where they use their deterministic base case projection, and then add a load for extreme outcomes with low probabilities, reflecting the increase in provisions their calculation methodologies would produce if their data had contained extreme events in the past. This load is the Events Not In Data ("ENID") item.

We have adopted a different approach, by taking the stochastic mean of the output from our Economic Capital Model, which generates extreme outcomes which we have not experienced in the past. For easy comparison with other firms, we have calculated the difference between the stochastic mean and the base case scenario, and called it ENID. This is because we use outputs from our stochastic model which generates events that haven't happened in the past.



#### D.2.3.9. Discounting

TPs are discounted at a risk-free rate under Solvency II. Under UK GAAP, there is no discounting allowed.

#### D.2.3.10. Other adjustments

#### D.2.4. Reinsurance Recoverable

AMIL has both quota-share and aggregate excess-of-loss ("XoL") reinsurance programs in place as at the end of 2017.

#### D.2.4.1. Quota-share reinsurance

We have placed the quota-share reinsurance with a pool of highly-rated (A or above) reinsurers for each underwriting year since 2011 till 2018, ceding 33.33% each year. This cession is increased to 50% for 2019 driven by the AmTrust's strategy of protecting its longer tail risk.

Due to the low loss ratios experienced on all business since 2011, the quota-share reinsurance recoveries in our TPs are small in relation to the overall value of the TPs.

#### D.2.4.2. Aggregate excess-of-loss reinsurance

We have one XoL treaty in place, covering extreme losses in Italy. The treaty covers business written from 2011-2017. Cover was initially placed to cover losses between the 80<sup>th</sup> and 99.5<sup>th</sup> percentiles. Since that time, the business has matured sufficiently for there to be no recoverables in our TPs for this treaty.

#### D.2.5. Material changes in assumptions for TPs

Since the previous reporting period, we have made no material changes in our assumptions.

## D.3. Other liabilities

#### D.3.1. Insurance & intermediaries payables

Insurance creditors are held at amortised cost under UK GAAP, due to the short term nature of these payables this is a reasonable approximation of fair value.

#### D.3.2. Payables (trade, not insurance)

All other creditors are held at amortised cost under UK GAAP, due to the short term nature of these payables this is a reasonable approximation of fair value.

#### D.3.3. Reinsurance payables

Under UK GAAP reinsurance payables comprise deferred ceding commission and reinsurance cash premiums payable.

Reinsurance creditor payable is held at amortised cost under UK GAAP, due to the short term nature of this payables this is a reasonable approximation of fair value.

Under Solvency II an adjustment is made removing the deferred ceding commission which is based on the UK GAAP accrual basis. These cash flows are dealt with in calculating the reinsurance technical provisions, using discounted cash flows under Solvency II. An adjustment is also made to move reinsurance premium payable which was due but not billed as at balance sheet date 31 December 2018 to reinsurance recoverable.

Category	UK GAAP	Reclassification	Valuation	Solvency II
(£'000)		Adjustment	Adjustment	
Reinsurance payables	6,430		(4,667)	1,763

# D.3.4. Other

Nothing noted.



## D.4. Alternative methods for valuation

## AMIL does not use any alternative methods for valuation.

D.5. Any other information

### D.5.1. Contingent Liabilities:

The Company may become liable for future claims in the event of the insolvency of the relevant lender. The Company is unable to quantify this contingent exposure, although the probability of any future liability is deemed extremely remote.

Under a settlement agreement with the lender in question the Company agreed to pay a capped amount of claims under the Master Policy. Since the loans were part of a securitization and the lender did not want to interrupt the payments into the securitization, the Company and the lender agreed to keep the terms of the Master Policy unchanged and have the lender accept all liability for claims payments in excess of the settlement amount. Therefore, the Company continues to pay claims as normal under the Master Policy even though the claims paid to date are far in excess of the settlement amount, and is being reimbursed for these excess payments. Should the lender default on the settlement agreement, the Company would remain liable under the terms of the Master Policy Agreement for payment to the investors. The Company has Letters of Comfort from the lender's Parent Companies should the lender become bankrupt and unable to honour its payment obligation to the Company under the settlement agreement.

# Capital Management

Section E



# E. Capital Management

# E.1.Own funds

# E.1.1. Management of Own Funds

We manage our Own Funds to ensure that the Company is adequately capitalised at all times and that all capital requirements are met. Our Capital Management Policy forms the basis for managing capital within AMIL and there has not been any material changes to the capital management policies and objectives. We determine capital adequacy on three different bases:

- 1. Economic Capital, establishing the appropriate risk-adjusted capital required to run the business using our Economic Capital Model ("ECM") on the appropriate economic basis;
- 2. Regulatory Capital, establishing a Solvency Capital Requirement ("SCR") under Solvency II; and
- 3. Rating Agency Capital, which establishes the appropriate capital support mechanisms to maintain the Company's external rating.

We assess capital requirements on a quarterly basis through the Company's ECM and SCR capital modelling processes. Economic capital is our critical measure of capital as it aligns most closely to the actual risks associated with the business. We have invested a lot of resources into the establishment of the ECM since 2008, which we use throughout our business for forecasting, strategic decision making and capital assessment and its outputs are consistently applied for pricing purposes.

The ECM assessment, at all times, includes a further 12 months of projected new business production which allows the prefunding of capital associated with the in-force portfolio and future business to be written in the near-term.

The premiums and losses projected by the ECM are used to calculate the Technical Provisions for the Solvency II Balance Sheet and SCR assessment which ensures alignment between the two capital regimes.

The ECM and associated governance is owned by the Risk and Actuarial teams which have a close interaction with the Board on at least a quarterly basis.

The business undergoes three formal planning processes which include capital sources and uses projections throughout the year:

- The long range forecast, or multi-year plan ("**Multi-Year Plan**"), is an annual process wherein we develop and discuss with our Board and Parent the strategic plan for the next 3 years. The Multi-Year Plan is developed taking into consideration, among other things, capital risks the Company is exposed to and forecasted changes to such risks, the anticipated changes in the market place, the competitive situation, and the business's own initiatives.
- The operating plan ("**Operating Plan**") is an annual process that establishes our plan for the following year. It is formalised by the Board at the time the final official financial plan or budget is approved. At such time the Board also considers the Operating Plan in the context of the tactical execution of the Multi-Year Plan.

The short range forecast ("**Short Range Forecast**") is a quarterly process undertaken by management. The Board will receive updates of such forecasts for the remainder of the Operating Plan period. It serves as an opportunity for refinement of the Operating Plan and the Short Range Forecast (remaining period of the financial year) presented in the previous quarter. This aides in determining capital requirements by assessing business volumes and performance against plan.



# E.1.2. Composition of Own Funds

£'000	Dec 2018	Dec 2017	Dec 2016
Ordinary share capital	67,688	67,688	141,016
Reconciliation reserve	7,401	7,388	(46,045)
Own funds	75,089	75,076	94,971

Note, of the above Own Funds, all are Tier 1, and 100% eligible towards the Company's SCR and MCR.

None of the Company's Own Funds are subject to transitional arrangements. We have no Ancillary Own Funds. There are no ring-fenced funds and no deductions are made from Own Funds, nor is there any restriction affecting the availability and transferability of Own Funds within the Company.

Material differences between equity in the financial statements, and the excess of assets over liabilities:

£'000	Dec 2018	Dec 2017	Dec 2016
Total reserves and retained earnings from UK GAAP Financials	72,147	71,410	112,431
Differences arising from SII Valuation of assets	(20,706)	(18,469)	(20,689)
Differences arising from SII Valuation of technical provisions	18,981	17,144	(320)
Differences arising from SII Valuation of other liabilities	4,667	4,991	3,549
Own funds per Solvency II	75,089	75,076	94,971

# E.2. Solvency capital requirement and minimum capital requirement

AMIL calculates its SCR and MCR using tools developed internally. These results then feed into an off-the-shelf system (VEGA, provided by Milliman) to contribute to the parent group's consolidated SCR and MCR.


Capital Requirements £'000	31 December 2018	31 December 2017
SCR	35,468	43,320
MCR	8,866	10,829


The key inputs to the Company's MCR calculation were the net best estimate and technical provisions calculated as a whole, and the net written premiums in the last twelve months for credit and suretyship class of business only.



	SF SCR 4Q18
Risk Category	SII Balance Sheet
	(£'000)
Market Risk	12,002
Counterparty Default Risk	2,047
Non-Life Underwriting Risk	27,991
Undiversified Basic SCR	42,040
Diversification credit	(7,845)
Basic SCR	34,195
Total Operational Risk	1,273
Standard Formula SCR	35,468
Available Capital	75,089
Capital Margin	39,622
Solvency Ratio	212%

	SF SCR 4Q17
Risk Category	SII Balance Sheet
	(£'000)
Market Risk	12,869
Counterparty Default Risk	1,946
Non-Life Underwriting Risk	35,586
Undiversified Basic SCR	50,401
Diversification credit	(8,610)
Basic SCR	41,791
Total Operational Risk	1,530
Standard Formula SCR	43,320
Available Capital	75,076
Capital Margin	31,756
Solvency Ratio	173%







AMIL does not use and Undertaking Specific Parameters (USPs). AMIL uses a simplified calculation for counterparty risk, whereby we treat all of our quota-share reinsurers as a single reinsurer with the rating of the lowest rated counterparty.

E.3. Use of duration-based equity risk sub-module in the calculation of Solvency Capital Requirement

AMIL does not use the duration-based equity risk sub-module in the calculation of its SCR.

E.4. Difference between the standard formula and the internal model used

# AMIL is a standard formula firm.

E.5.Non- compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement

# AMIL has been in compliance with the MCR and SCR throughout the reporting period.

E.6.Any other information

None noted.

# Annex

Quantitative Reporting Templates

# AMT Financial Mortgage Insurance Limited

Solvency and Financial Condition Report

Disclosures

<sup>31</sup> December **2018** 

(Monetary amounts in GBP thousands)

#### General information

Undertaking name	AMT Financial Mortgage Insurance Limited
Undertaking identification code	213800MKOTU7JZ82L809
Type of code of undertaking	LEI
Type of undertaking	Non-life undertakings
Country of authorisation	GB
Language of reporting	en
Reporting reference date	31 December 2018
Currency used for reporting	GBP
Accounting standards	Local GAAP
Method of Calculation of the SCR	Standard formula
Matching adjustment	No use of matching adjustment
Volatility adjustment	No use of volatility adjustment
Transitional measure on the risk-free interest rate	No use of transitional measure on the risk-free interest rate
Transitional measure on technical provisions	No use of transitional measure on technical provisions

#### List of reported templates

S.02.01.02 - Balance sheet

S.05.01.02 - Premiums, claims and expenses by line of business

 $\ensuremath{\mathsf{S.05.02.01}}$  - Premiums, claims and expenses by country

S.17.01.02 - Non-Life Technical Provisions

S.19.01.21 - Non-Life insurance claims

S.23.01.01 - Own Funds

S.25.01.21 - Solvency Capital Requirement - for undertakings on Standard Formula

S.28.01.01 - Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

# S.02.01.02 Balance sheet

AssetsC0010R0030Intangible assetsC0010R0040Deferred tax assets		Balance sneet	
R0030       Intangible assets         R0040       Deferred tax assets         R0050       Persion benefit surplus         R0060       Property, plant & equipment held for own use       19         R0070       Investments (other than assets held for index-linked and unit-linked contracts)       124,888         R0080       Property, (other than assets held for index-linked and unit-linked contracts)       0         R0070       Holdings in related undertakings, including participations       3,989         R0110       Equities - unisted       0         R0110       Equities - unisted       0         R0110       Equities - unisted       120,812         R0110       Government Bonds       2,254         R0110       Government Bonds       2,254         R0110       Collateralised securities       0         R0110       Collateralised securities       0         R0110       Collateralised securities       0         R0120       Derivatives			Solvency II value
R0040       Deferred tax assets         R0050       Pension benefit surplus         R0050       Property, plant & equipment held for own use       19         R0070       Investments (other than assets held for index-linked and unit-linked contracts)       124.828         R0080       Property (other than assets held for index-linked and unit-linked contracts)       3,989         R0090       Holdings in related undertakings, including participations       3,989         R0100       Equities - isted       0         R0110       Equities - isted       0         R0110       Equities - unlisted       120,812         R0140       Government Bonds       2,254         R0150       Corporate Bonds       185,558         R0160       Structured notes       0         R0170       Collateralised securities       0         R0180       Collective Investments Undertakings       87         R0200       Deposits other than cash equivalents       0         R0210       Other Investments       0         R0220       Assets held for index-linked and unit-linked contracts       0         R0210       Lans and mortgages       0         R0220       Lans and mortgages       0         R0220       Lans and		Assets	C0010
R0050       Pension benefit surplus       19         R0050       Property, plant & equipment held for own use       19         R0070       Investments (other than assets held for index-linked and unit-linked contracts)       124,888         R0080       Property (other than for own use)       0         R0070       Equities : unisted       3,989         R0110       Equities : unisted       0         R01120       Equities : unisted       120,812         R01130       Bonds       120,812         R0140       Government Bonds       2,254         R0150       Corporate Bonds       118,555         R0160       Structured notes       0         R0170       Collateralised securities       0         R0180       Collective Investments Undertakings       87         R0190       Derivatives       0         R0210       Other Investments       0         R0220       Assets held for index-linked and unit-linked contracts       0         R0220       Lans and mortgages       0         R0220       Loans and mortgages       0         R0220       Other Investiments ismilar to non-life       3,741         R0290       Non-life excluding health       3,741	R0030	Intangible assets	
R0060     Property, plant & equipment held for own use     19       R0070     Investments (other than assets held for index-linked and unit-linked contracts)     124,888       R0080     Property (other than for own use)     0       R0070     Equities     0       R0110     Equities - listed     0       R0110     Equities - unisted     0       R0110     Equities - unisted     0       R0110     Equities - unisted     0       R0110     Government Bonds     2,254       R0160     Structured notes     0       R0160     Structured notes     0       R0170     Collateralised securities     0       R0180     Collective Investments Undertakings     87       R0190     Derivatives     0       R0200     Deposits other than cash equivalents     0       R0210     Other investments     0       R0220     Assets held for index-linked and unit-linked contracts     0       R0210     Other investments     0       R0214	R0040	Deferred tax assets	
R0070       Investments (other than assets held for index-linked and unit-linked contracts)       124,888         R0080       Property (other than for own use)       0         R0090       Holdings in related undertakings, including participations       3,989         R0110       Equities - unisted       0         R0110       Equities - unisted       120,812         R0110       Government Bonds       2,254         R0110       Government Bonds       2,254         R0110       Collacterialised securities       0         R0110       Collacterialised securities       0         R0110       Collacterialised securities       0         R0110       Collacterialised securities       0         R0110       Derivatives       0         R0120       Deposits other than cash equivalents       0         R0210       Other investments       0         R0220       Loans and mortgages       0         R0210       Loans and mortgages       0         R0220       Loans and mortgages       0         R0210       Loans and mortgages       0         R0220       Loans and mortgages       0         R0210       Loans and mortgages       0         R0220 </td <td>R0050</td> <td>Pension benefit surplus</td> <td></td>	R0050	Pension benefit surplus	
R0080       Property (other than for own use)       0         R0090       Holdings in related undertakings, including participations       3,989         R0100       Equities is in related undertakings, including participations       0         R0110       Equities - listed       0         R01120       Equities - unlisted       0         R01120       Equities - unlisted       2,254         R01140       Government Bonds       2,254         R0150       Corporate Bonds       118,558         R0160       Structured notes       0         R0170       Collateralised securities       0         R0180       Collective Investments Undertakings       87         R01200       Deposits other than cash equivalents       0         R02100       Deposits other than cash equivalents       0         R02201       Assets held for index-linked and unit-linked contracts       0         R02202       Loans and mortgages       0       0         R02101       Loans and mortgages to individuals       0       0         R02201       Loans and mortgages to individuals       0       0         R02101       Life and health similar to non-life       3,741       3,741         R02201       Leant health	R0060	Property, plant & equipment held for own use	19
R0090       Holdings in related undertakings, including participations       3,989         R0110       Equities       0         R0110       Equities - listed       0         R0110       Equities - unlisted       0         R0110       Equities - unlisted       0         R0130       Bonds       120,812         R0140       Government Bonds       2,254         R0150       Corporate Bonds       118,558         R0160       Structured notes       0         R0170       Collateralised securities       0         R0180       Collective Investments Undertakings       87         R0200       Deposits other than cash equivalents       0         R0210       Other investments       0         R0210       Other investments       0         R0210       Collective loans and mortgages       0         R0210	R0070	Investments (other than assets held for index-linked and unit-linked contracts)	124,888
R0100       Equities         R0110       Equities - listed         R0120       Equities - unlisted         R0130       Bonds         R0140       Government Bonds         R0150       Corporate Bonds         R0160       Structured notes         R0170       Collateralised securities         R0170       Collateralised securities         R0170       Collateralised securities         R0170       Derivatives         R0200       Deposits other than cash equivalents         R0210       Other investments         R0220       Assets held for index-linked and unit-linked contracts         R0220       Loans and mortgages         R0260       Other loans and mortgages         R0270       Reinsurance recoverables from:         R0270       Reinsurance recoverables from:         R0270       Non-life and health similar to non-life         R0280       Life and health similar to non-life         R0310       Life and health and index-linked and unit-linked         R0320       Health similar to life, excluding index-linked and unit-linked         R0330       Life excluding health and index-linked and unit-linked         R0340       Life index-linked and unit-linked         R0350 </td <td>R0080</td> <td>Property (other than for own use)</td> <td>0</td>	R0080	Property (other than for own use)	0
R0110       Equities - listed         R0120       Equities - unlisted         R0130       Bonds       120,812         R0140       Government Bonds       2,254         R0150       Corporate Bonds       118,558         R0160       Structured notes       0         R0170       Collateralised securities       0         R0190       Derivatives       87         R0200       Deposits other than cash equivalents       0         R0210       Other investments       0         R0220       Deposits other than cash equivalents       0         R0210       Other investments       0         R0220       Loans on policies       0         R0210       Other investments       0         R0220       Loans and mortgages       0         R0240       Loans and mortgages       0         R0250       Loans and mortgages       0         R0270       Reinsurance recoverables from:       3,741         R0280       Non-life excluding health       3,741         R0290       Health similar to non-life       0         R0310       Life and health similar to non-life       0         R0310       Life excluding health and index-l	R0090	Holdings in related undertakings, including participations	3,989
R0120       Equities - unlisted         R0130       Bonds         R0140       Government Bonds         R0150       Corporate Bonds         R0160       Structured notes         R0170       Collateralised securities         R0180       Callective Investments Undertakings         R0190       Derivatives         R0200       Deposits other than cash equivalents         R0210       Other investments         R0210       Other investments         R0220       Assets held for index-linked and unit-linked contracts         R0220       Assets held for index-linked and unit-linked contracts         R0220       Loans on policies         R0220       Cother loans and mortgages         R0220       Non-life and health similar to non-life         R0220       Non-life excluding health         R0220       Non-life excluding health         R0210       Health similar to non-life         R0220       Non-life excluding health         R0210       Health similar to non-life         R0220       Health similar to life, excluding index-lin	R0100	Equities	0
R0130Bonds120.812R0140Government Bonds2,254R0150Corporate Bonds118,558R0160Structured notes0R0170Collateralised securities0R0180Collective Investments Undertakings837R0190Derivatives0R0210Other investments0R0220Assets held for index-linked and unit-linked contracts0R0230Loans and mortgages0R0240Loans on policies0R0250Other loans and mortgages0R0270Reinsurance recoverables from:3,741R0290Non-life and health similar to non-life3,741R0300Life and health similar to life, excluding index-linked and unit-linked0R0310Life excluding health0R0330Life excluding health and index-linked and unit-linked0R0340Life index-linked and unit-linked0R0350Deposits to cedants0R0360Reinsurance receivables407R0360Reinsurance receivables4067R0360Receivables (trade, not insurance)55R0360Receivables (trade, not insurance)55R0370Cash and cash equivalents4,095R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown55	R0110	Equities - listed	
R0140Government Bonds2,254R0150Corporate Bonds118,558R0160Structured notes0R0170Collateralised securities0R0180Callective Investments Undertakings87R0190Derivatives0R0210Other investments0R0220Assets held for index-linked and unit-linked contracts0R0230Loans and mortgages0R0240Loans and mortgages0R0250Loans and mortgages0R0260Other loans and mortgages0R0270Reinsurance recoverables from:3,741R0280Non-life and health similar to non-life3,741R0300Health similar to non-life0R0310Life and health similar to life, excluding index-linked and unit-linked0R0330Life excluding health and index-linked and unit-linked0R0340Leifi index-linked and unit-linked0R0350Deposits to cedants0R0360Insurance receivables1,708R0370Reinsurance receivables4467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)0R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown4,095	R0120	Equities - unlisted	
R0150Corporate Bonds118,558R0160Structured notes0R0170Collateralised securities0R0180Collective Investments Undertakings87R0190Derivatives0R0200Deposits other than cash equivalents0R0210Other investments0R0220Assets held for index-linked and unit-linked contracts0R0230Loans and mortgages0R0240Loans and mortgages to individuals0R0250Loans and mortgages3,741R0260Other loans and mortgages3,741R0270Reinsurance recoverables from:3,741R0280Non-life and health similar to non-life3,741R0300Health similar to life, excluding index-linked and unit-linked0R0310Life and health similar to life, excluding index-linked and unit-linked0R0310Life excluding health and index-linked and unit-linked0R0310Life index-linked and unit-linked0R0310Life index-linked and unit-linked0R0310Reinsurance receivables1,708R0320Reinsurance receiv	R0130	Bonds	120,812
R0160       Structured notes       0         R0170       Collateralised securities       0         R0180       Collective Investments Undertakings       87         R0190       Derivatives       0         R0200       Deposits other than cash equivalents       0         R0210       Other investments       0         R0220       Assets held for index-linked and unit-linked contracts       0         R0230       Loans and mortgages       0         R0240       Loans on policies       0         R0250       Loans and mortgages to individuals       0         R0260       Other loans and mortgages       0         R0270       Reinsurance recoverables from:       3,741         R0280       Non-life and health similar to non-life       3,741         R0300       Health similar to non-life       0         R0310       Life and health similar to life, excluding index-linked and unit-linked       0         R0310       Life excluding health an index-linked and unit-linked       0         R0310       Life excluding health an index-linked and unit-linked       0         R0330       Life excluding health an index-linked and unit-linked       0         R0330       Life excluding health an index-linked and unit-linked <td>R0140</td> <td>Government Bonds</td> <td>2,254</td>	R0140	Government Bonds	2,254
R0170Collateralised securities0R0180Collective Investments Undertakings87R0190Derivatives0R0200Deposits other than cash equivalents0R0210Other investments0R0220Assets held for index-linked and unit-linked contracts0R0230Loans and mortgages0R0240Loans and mortgages to individuals0R0250Loans and mortgages0R0270Reinsurance recoverables from:3,741R0280Non-life and health similar to non-life3,741R0300Health similar to non-life0R0310Life and health similar to life, excluding index-linked and unit-linked0R0330Life index-linked and unit-linked and unit-linked0R0330Life index-linked and unit-linked0R0340Life index-linked and unit-linked0R0350Deposits to cedants0R0360Insurance and intermediaries receivables1,708R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)55R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown4,095	R0150	Corporate Bonds	118,558
R0180Collective Investments Undertakings87R0190Derivatives0R0200Deposits other than cash equivalents0R0210Other investments0R0220Assets held for index-linked and unit-linked contracts0R0220Loans and mortgages0R0240Loans on policies0R0250Loans and mortgages to individuals0R0260Other loans and mortgages0R0270Reinsurance recoverables from:3,741R0280Non-life and health similar to non-life3,741R0300Health similar to life, excluding index-linked and unit-linked0R0310Life and health similar to life, excluding index-linked and unit-linked0R0320Health similar to life0R0330Life index-linked and unit-linked and unit-linked0R0340Life index-linked and unit-linked and unit-linked0R0350Deposits to cedants0R0360Insurance and intermediaries receivables1,708R0370Reinsurance receivables4407R0380Receivables (trade, not insurance)55R0390Own shares (held directly)0R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown4,095	R0160	Structured notes	0
R0190       Derivatives         R0200       Deposits other than cash equivalents       0         R0210       Other investments       0         R0220       Assets held for index-linked and unit-linked contracts       0         R0220       Loans and mortgages       0         R0240       Loans and mortgages to individuals       0         R0250       Loans and mortgages to individuals       0         R0260       Other loans and mortgages       0         R0270       Reinsurance recoverables from:       3,741         R0280       Non-life and health similar to non-life       3,741         R0290       Non-life excluding health       3,741         R0300       Health similar to non-life       0         R0310       Life and health similar to life, excluding index-linked and unit-linked       0         R0320       Health similar to life, excluding index-linked and unit-linked       0         R0330       Life excluding health and index-linked and unit-linked       0         R0340       Life index-linked and unit-linked and unit-linked       0         R0350       Deposits to cedants       0         R0360       Insurance and intermediaries receivables       1,708         R0360       Insurance receivables <td< td=""><td>R0170</td><td>Collateralised securities</td><td>0</td></td<>	R0170	Collateralised securities	0
R0200       Deposits other than cash equivalents       0         R0210       Other investments       0         R0220       Assets held for index-linked and unit-linked contracts       0         R0230       Loans and mortgages       0         R0240       Loans and mortgages to individuals       0         R0250       Loans and mortgages to individuals       0         R0260       Other loans and mortgages       0         R0270       Reinsurance recoverables from:       3,741         R0280       Non-life and health similar to non-life       3,741         R0290       Non-life excluding health       3,741         R0310       Health similar to non-life       0         R0310       Life and health similar to life, excluding index-linked and unit-linked       0         R0320       Health similar to life       0         R0330       Life excluding health and index-linked and unit-linked       0         R0340       Life index-linked and unit-linked       0         R0350       Deposits to cedants       0       0         R0361       Insurance and intermediaries receivables       1,708       1,708         R0370       Reinsurance receivables       55       55         R0380       Receiv	R0180	Collective Investments Undertakings	87
R0210       Other investments       0         R0220       Assets held for index-linked and unit-linked contracts       0         R0230       Loans and mortgages       0         R0240       Loans and mortgages to individuals       0         R0250       Loans and mortgages to individuals       0         R0260       Other loans and mortgages       0         R0270       Reinsurance recoverables from:       3,741         R0280       Non-life and health similar to non-life       3,741         R0290       Non-life excluding health       3,741         R0300       Health similar to non-life       0         R0310       Life and health similar to life, excluding index-linked and unit-linked       0         R0320       Health similar to life       0         R0330       Life excluding health and index-linked and unit-linked       0         R0340       Life index-linked and unit-linked       0         R0350       Deposits to cedants       0       0         R0361       Insurance and intermediaries receivables       1,708         R0370       Reinsurance receivables       55         R0380       Receivables (trade, not insurance)       55         R0380       Receivables (trade, not insurance)	R0190	Derivatives	
R0220       Assets held for index-linked and unit-linked contracts       0         R0230       Loans and mortgages       0         R0240       Loans on policies       0         R0250       Loans and mortgages to individuals       0         R0260       Other loans and mortgages       0         R0270       Reinsurance recoverables from:       3,741         R0280       Non-life and health similar to non-life       3,741         R0290       Non-life excluding health       3,741         R0300       Health similar to non-life       3,741         R0300       Health similar to life, excluding index-linked and unit-linked       0         R0310       Life and health similar to life, excluding index-linked and unit-linked       0         R0320       Health similar to life       0         R0330       Life excluding health and index-linked and unit-linked       0         R0330       Life excluding health and index-linked and unit-linked       0         R0330       Life index-linked and unit-linked       0         R0340       Life excluding health and index-linked and unit-linked       0         R0350       Deposits to cedants       0         R0360       Insurance and intermediaries receivables       1,708         R03	R0200	Deposits other than cash equivalents	0
R0230Loans and mortgages0R0240Loans on policies0R0250Loans and mortgages to individuals0R0260Other loans and mortgages3,741R0260Non-life and health similar to non-life3,741R0290Non-life and health similar to non-life3,741R0300Health similar to non-life0R0310Life and health similar to life, excluding index-linked and unit-linked0R0320Health similar to life0R0330Life excluding health and index-linked and unit-linked0R0340Life index-linked and unit-linked0R0350Deposits to cedants0R0360Insurance receivables1,708R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)0R0410Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Any other assets, not elsewhere shown4,095	R0210	Other investments	0
R0240       Loans on policies       0         R0250       Loans and mortgages to individuals       0         R0260       Other loans and mortgages       3,741         R0280       Non-life and health similar to non-life       3,741         R0290       Non-life excluding health       3,741         R0200       Health similar to non-life       3,741         R0300       Health similar to non-life       0         R0310       Life and health similar to life, excluding index-linked and unit-linked       0         R0320       Health similar to life       0         R0330       Life excluding health and index-linked and unit-linked       0         R0340       Life index-linked and unit-linked       0         R0350       Deposits to cedants       0         R0360       Insurance and intermediaries receivables       1,708         R0370       Reinsurance receivables       467         R0380       Receivables (trade, not insurance)       55         R0390       Own shares (held directly)       0         R0400       Amounts due in respect of own fund items or initial fund called up but not yet paid in       0         R0410       Cash and cash equivalents       4,095         R0420       Any other assets, not elsewh	R0220	Assets held for index-linked and unit-linked contracts	
R0250Loans and mortgages to individualsR0260Other loans and mortgagesR0270Reinsurance recoverables from:R0280Non-life and health similar to non-lifeR0290Non-life excluding healthR0300Health similar to non-lifeR0310Life and health similar to life, excluding index-linked and unit-linkedR0320Health similar to lifeR0330Life excluding health and index-linked and unit-linkedR0340Life index-linked and unit-linkedR0350Deposits to cedantsR0360Insurance and intermediaries receivablesR0370Reinsurance receivablesR0380Receivables (trade, not insurance)R0390Own shares (held directly)R0400Amounts due in respect of own fund items or initial fund called up but not yet paid inR0410Cash and cash equivalentsR0420Any other assets, not elsewhere shown	R0230	Loans and mortgages	0
R0260Other loans and mortgagesR0270Reinsurance recoverables from:3,741R0280Non-life and health similar to non-life3,741R0290Non-life excluding health3,741R0300Health similar to non-life0R0310Life and health similar to life, excluding index-linked and unit-linked0R0320Health similar to life0R0330Life excluding health and index-linked and unit-linked0R0340Life index-linked and unit-linked0R0350Deposits to cedants0R0360Insurance and intermediaries receivables1,708R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown0	R0240	Loans on policies	0
R0270Reinsurance recoverables from:3,741R0280Non-life and health similar to non-life3,741R0290Non-life excluding health3,741R0300Health similar to non-life0R0310Life and health similar to life, excluding index-linked and unit-linked0R0320Health similar to life0R0330Life excluding health and index-linked and unit-linked0R0340Life index-linked and unit-linked0R0350Deposits to cedants0R0360Insurance and intermediaries receivables1,708R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)55R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown1	R0250	Loans and mortgages to individuals	
R0280Non-life and health similar to non-life3,741R0290Non-life excluding health3,741R0300Health similar to non-life0R0310Life and health similar to life, excluding index-linked and unit-linked0R0320Health similar to life0R0330Life excluding health and index-linked and unit-linked0R0340Life index-linked and unit-linked0R0350Deposits to cedants0R0360Insurance and intermediaries receivables1,708R0370Recievables (trade, not insurance)55R0390Own shares (held directly)55R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown1	R0260	Other loans and mortgages	
R0290Non-life excluding health3,741R0300Health similar to non-life0R0310Life and health similar to life, excluding index-linked and unit-linked0R0320Health similar to life0R0330Life excluding health and index-linked and unit-linked0R0340Life index-linked and unit-linked0R0350Deposits to cedants0R0360Insurance and intermediaries receivables1,708R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)0R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown0	R0270	Reinsurance recoverables from:	3,741
R0300Health similar to non-life0R0310Life and health similar to life, excluding index-linked and unit-linked0R0320Health similar to life0R0330Life excluding health and index-linked and unit-linked0R0340Life index-linked and unit-linked0R0350Deposits to cedants0R0360Insurance and intermediaries receivables1,708R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown0	R0280	Non-life and health similar to non-life	3,741
R0310Life and health similar to life, excluding index-linked and unit-linked0R0320Health similar to life0R0330Life excluding health and index-linked and unit-linked0R0340Life index-linked and unit-linked0R0350Deposits to cedants0R0360Insurance and intermediaries receivables1,708R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)0R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown0	R0290	Non-life excluding health	3,741
R0320Health similar to lifeR0330Life excluding health and index-linked and unit-linkedR0340Life index-linked and unit-linkedR0350Deposits to cedantsR0360Insurance and intermediaries receivablesR0370Reinsurance receivablesR0380Receivables (trade, not insurance)R0390Own shares (held directly)R0400Amounts due in respect of own fund items or initial fund called up but not yet paid inR0410Cash and cash equivalentsR0420Any other assets, not elsewhere shown	R0300	Health similar to non-life	0
R0330Life excluding health and index-linked and unit-linkedR0340Life index-linked and unit-linkedR0350Deposits to cedantsR0360Insurance and intermediaries receivablesR0370Reinsurance receivablesR0380Receivables (trade, not insurance)R0390Own shares (held directly)R0400Amounts due in respect of own fund items or initial fund called up but not yet paid inR0410Cash and cash equivalentsR0420Any other assets, not elsewhere shown	R0310	Life and health similar to life, excluding index-linked and unit-linked	0
R0340Life index-linked and unit-linkedR0350Deposits to cedants0R0360Insurance and intermediaries receivables1,708R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)55R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown1	R0320	Health similar to life	
R0350Deposits to cedants0R0360Insurance and intermediaries receivables1,708R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)55R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown1	R0330	Life excluding health and index-linked and unit-linked	
R0360Insurance and intermediaries receivables1,708R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)55R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown1,708	R0340	Life index-linked and unit-linked	
R0370Reinsurance receivables467R0380Receivables (trade, not insurance)55R0390Own shares (held directly)55R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown1	R0350	Deposits to cedants	0
R0380Receivables (trade, not insurance)55R0390Own shares (held directly)55R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown1	R0360	Insurance and intermediaries receivables	1,708
R0390Own shares (held directly)R0400Amounts due in respect of own fund items or initial fund called up but not yet paid inR0410Cash and cash equivalentsR0420Any other assets, not elsewhere shown	R0370	Reinsurance receivables	467
R0400Amounts due in respect of own fund items or initial fund called up but not yet paid in0R0410Cash and cash equivalents4,095R0420Any other assets, not elsewhere shown	R0380	Receivables (trade, not insurance)	55
R0410       Cash and cash equivalents       4,095         R0420       Any other assets, not elsewhere shown	R0390	Own shares (held directly)	
R0420 Any other assets, not elsewhere shown	R0400	Amounts due in respect of own fund items or initial fund called up but not yet paid in	0
	R0410	Cash and cash equivalents	4,095
R0500 Total assets134,972	R0420	Any other assets, not elsewhere shown	
	R0500	Total assets	134,972

# S.02.01.02 Balance sheet

		Solvency II value
	Liabilities	C0010
R0510	Technical provisions - non-life	46,486
R0520	Technical provisions - non-life (excluding health)	46,486
R0530	TP calculated as a whole	0
R0540	Best Estimate	42,464
R0550	Risk margin	4,022
R0560	Technical provisions - health (similar to non-life)	0
R0570	TP calculated as a whole	0
R0580	Best Estimate	0
R0590	Risk margin	0
R0600	Technical provisions - life (excluding index-linked and unit-linked)	0
R0610	Technical provisions - health (similar to life)	0
R0620	TP calculated as a whole	
R0630	Best Estimate	
R0640	Risk margin	
R0650	Technical provisions - life (excluding health and index-linked and unit-linked)	0
R0660	TP calculated as a whole	
R0670	Best Estimate	
R0680	Risk margin	
R0690	Technical provisions - index-linked and unit-linked	0
R0700	TP calculated as a whole	
R0710	Best Estimate	
R0720	Risk margin	
R0740	Contingent liabilities	
R0750	Provisions other than technical provisions	
R0760	Pension benefit obligations	325
R0770	Deposits from reinsurers	
R0780	Deferred tax liabilities	
R0790	Derivatives	
R0800	Debts owed to credit institutions	
R0810	Financial liabilities other than debts owed to credit institutions	
R0820	Insurance & intermediaries payables	
R0830	Reinsurance payables	1,438
R0840	Payables (trade, not insurance)	11,634
R0850	Subordinated liabilities	0
R0860	Subordinated liabilities not in BOF	
R0870	Subordinated liabilities in BOF	0
R0880	Any other liabilities, not elsewhere shown	
R0900	Total liabilities	59,882
R1000	Excess of assets over liabilities	75,089

#### S.05.01.02 Premiums, claims and expenses by line of business

#### Non-life

	Line of Business for: non-life insurance and reinsurance obligations (direct business and accepted proportional reinsurance)																	
	Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Misc. financial loss	Health	Casualty	Marine, aviation and transport	Property	Total	
	C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0200	
Premiums written																		
R0110 Gross - Direct Business									9,941								9,941	
R0120 Gross - Proportional reinsurance accepted																	0	
R0130 Gross - Non-proportional reinsurance accepted																	0	
R0140 Reinsurers' share									3,208								3,208	
R0200 Net									6,733								6,733	
Premiums earned																		
R0210 Gross - Direct Business									12,437								12,437	
R0220 Gross - Proportional reinsurance accepted																	0	
R0230 Gross - Non-proportional reinsurance accepted																	0	
R0240 Reinsurers' share									4,078								4,078	
R0300 Net									8,360								8,360	
Claims incurred																		
R0310 Gross - Direct Business									2,079								2,079	
R0320 Gross - Proportional reinsurance accepted														1			0	
R0330 Gross - Non-proportional reinsurance accepted																	0	
R0340 Reinsurers' share									749								749	
R0400 Net									1,330								1,330	
Changes in other technical provisions		1	1	1	1	1												
R0410 Gross - Direct Business																	0	
R0420 Gross - Proportional reinsurance accepted																	0	
R0430 Gross - Non-proportional reinsurance accepted																	0	
R0440 Reinsurers' share																	0	
R0500 Net									0								0	
R0550 Expenses incurred									5,839								5,839	
R1200 Other expenses			-	-		-								-				
R1300 Total expenses																	5,839	

# S.05.02.01 Premiums, claims and expenses by country

### Non-life

		C0010	C0020	C0030	C0040	C0050	C0060	C0070
		Home Country	Top 5 countries (by n	amount of gross pre on-life obligations	emiums written) -	Top 5 countries (by premiums writi obliga	en) - non-life	Total Top 5 and home country
R0010			т	DE	SE	IR	РТ	nome country
		C0080	C0090	C0100	C0110	C0120	C0130	C0140
	Premiums written							
R0110	Gross - Direct Business	1,194	6,280	2,411	56			9,941
R0120	Gross - Proportional reinsurance accepted							0
R0130	Gross - Non-proportional reinsurance accepted							0
R0140	Reinsurers' share	397	2,249	557				3,204
R0200	Net	797	4,031	1,853	56	0	0	6,737
	Premiums earned							
R0210	Gross - Direct Business	1,479	8,506	2,185	81	94	50	12,396
R0220	Gross - Proportional reinsurance accepted							0
R0230	Gross - Non-proportional reinsurance accepted							0
R0240	Reinsurers' share	488	3,052	528				4,068
R0300	Net	991	5,454	1,658	81	94	50	8,328
	Claims incurred							
R0310	Gross - Direct Business	-58	1,737	294	-17	201	13	2,171
R0320	Gross - Proportional reinsurance accepted							0
R0330	Gross - Non-proportional reinsurance accepted							0
R0340	Reinsurers' share	11	608	106				725
R0400	Net	-69	1,129	189	-17	201	13	1,446
	Changes in other technical provisions							
R0410	Gross - Direct Business							0
R0420	Gross - Proportional reinsurance accepted							0
R0430	Gross - Non-proportional reinsurance accepted							0
R0440	Reinsurers' share							0
R0500	Net	0	0	0	0	0	0	0
R0550	Expenses incurred	389	3,769	364	-44	343	56	4,876
R1200	Other expenses							
R1300	Total expenses							4,876

#### S.17.01.02 Non-Life Technical Provisions

					Direct bus	iness and accept	ed proportional re	insurance					Ac	cepted non-prop	ortional reinsura	nce	
	Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss	Non- proportional health reinsurance	Non- proportional casualty reinsurance	Non- proportional marine, aviation and transport reinsurance	Non- proportional property reinsurance	Total Non-Life obligation
	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0170	C0180
R0010 Technical provisions calculated as a whole									C	1							0
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole																	0
Technical provisions calculated as a sum of BE and RM Best estimate																	
Premium provisions			1	1	1	1			1					1	1		
R0060 Gross									16,567								16,567
R0140 Total recoverable from reinsurance/SPV and Finite R0140 Re after the adjustment for expected losses due to counterparty default									3,428								3,428
R0150 Net Best Estimate of Premium Provisions									13,138								13,138
Claims provisions																	
R0160 Gross									25,898								25,898
R0240 Total recoverable from reinsurance/SPV and Finite R0240 Re after the adjustment for expected losses due to counterparty default									313								313
R0250 Net Best Estimate of Claims Provisions									25,585								25,585
R0260 Total best estimate - gross									42,464								42,464
R0270 Total best estimate - net									38,723								38,723
R0280 Risk margin						1			4,022							1	4,022
•									4,022								4,022
Amount of the transitional on Technical Provisions		1		1		1	1		1			1		1	1		
R0290 Technical Provisions calculated as a whole R0300 Best estimate																	0
R0310 Risk margin																	0
·		1	1	1		I				1 1		1			I		-
R0320 Technical provisions - total									46,486								46,486
Recoverable from reinsurance contract/SPV and R0330 Finite Re after the adjustment for expected losses due to counterparty default - total									3,741								3,741
R0340 Technical provisions minus recoverables from reinsurance/SPV and Finite Re - total									42,745								42,745

#### S.19.01.21 Non-Life insurance claims

#### Total Non-life business

Z0020

Accident year / underwriting year Underwriting Year

	Gross Claims	Paid (non-cum	nulative)											
	(absolute am	ount)												
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0170	C0180
	Year					Developm	ent year						In Current	Sum of years
		0	1	2	3	4	5	6	7	8	9	10 & +	year	(cumulative)
0100	Prior											6,176	6,176	6,176
0160	2009	0	0	88	565	360	189	143	1,645	224	773		773	3,986
0170	2010	0	6	256	115	49	20	716	106	411			411	1,679
0180	2011	0	0	8	10	0	87	785	0				0	890
190	2012	0	0	0	47	170	0	120					120	337
200	2013	0	0	0	0	24	0						0	24
)210	2014	0	0	0	12	0							0	12
)220	2015	0	0	0	13								13	13
)230	2016	0	0	0									0	0
)240	2017	0	0										0	0
)250	2018	0											0	0
260												Total	7,492	13,116

F	Gross Undisc	ounted Best Es	stimate Clain	ns Provisions									
	(absolute am	ount)											
													C0360
		C0200	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0290	C0300	Year end
	Year					Developm	nent year						(discounted
		0	1	2	3	4	5	6	7	8	9	10 & +	data)
R0100	Prior											16,415	16,399
R0160	2009	0	0	0	0	0	0	0	0	0	1,966		1,963
R0170	2010	0	0	0	0	0	0	0	0	870			869
R0180	2011	0	0	0	0	0	0	0	661				657
R0190	2012	0	0	0	0	0	0	282					280
R0200	2013	0	0	0	0	0	235						235
R0210	2014	0	0	0	0	271							272
R0220	2015	0	0	0	172								171
R0230	2016	0	0	254									253
R0240	2017	0	102										101
R0250	2018	38											38
R0260												Total	21,236

#### S.23.01.01 **Own Funds**

#### Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35

- R0010 Ordinary share capital (gross of own shares)
- R0030 Share premium account related to ordinary share capital
- R0040 Initial funds, members' contributions or the equivalent basic own-fund item for mutual and mutual-type undertakings
- R0050 Subordinated mutual member accounts
- R0070 Surplus funds
- R0090 Preference shares
- R0110 Share premium account related to preference shares
- R0130 Reconciliation reserve
- R0140 Subordinated liabilities
- R0160 An amount equal to the value of net deferred tax assets
- R0180 Other own fund items approved by the supervisory authority as basic own funds not specified above

#### R0220 Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds

- R0230 Deductions for participations in financial and credit institutions
- R0290 Total basic own funds after deductions

#### Ancillary own funds

- R0300 Unpaid and uncalled ordinary share capital callable on demand
- R0310 Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual type undertakings, callable on demand
- R0320 Unpaid and uncalled preference shares callable on demand
- R0330 A legally binding commitment to subscribe and pay for subordinated liabilities on demand
- R0340 Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC
- R0350 Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC
- R0360 Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC
- R0370 Supplementary members calls other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC
- R0390 Other ancillary own funds
- R0400 Total ancillary own funds

#### Available and eligible own funds

- R0500 Total available own funds to meet the SCR
- R0510 Total available own funds to meet the MCR
- R0540 Total eligible own funds to meet the SCR
- R0550 Total eligible own funds to meet the MCR

#### R0580 SCR

- R0600 MCR
- R0620 Ratio of Eligible own funds to SCR
- R0640 Ratio of Eligible own funds to MCR

#### Reconcilliation reserve

R0700	Excess of assets over liabilities
R0710	Own shares (held directly and indirectly)

- R0720 Foreseeable dividends, distributions and charges
- R0730 Other basic own fund items
- R0740 Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds
- R0760 Reconciliation reserve

#### Expected profits

- R0770 Expected profits included in future premiums (EPIFP) Life business
- R0780 Expected profits included in future premiums (EPIFP) Non- life business
- R0790 Total Expected profits included in future premiums (EPIFP)

Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
C0010	C0020	C0030	C0040	C0050
67,688	67,688		0	
0	0		0	
0	0		0	
0		0	0	0
0	0			
0		0	0	0
0		0	0	0
7,402	7,402			
0		0	0	0
0				0
0	0	0	0	0
0				
0	0	0	0	
75,089	75,089	0	0	0



0	0	0	75,089	75,089
	0	0	75,089	75,089
0	0	0	75,089	75,089
	0	0	75,089	75,089

35,469
8,867
211.70%
846.82%
C0060





# S.25.01.21 Solvency Capital Requirement - for undertakings on Standard Formula

	R0010	Market	risk
--	-------	--------	------

R0020 Counterparty default risk

R0030 Life underwriting risk

R0040 Health underwriting risk

R0050 Non-life underwriting risk

R0060 Diversification

R0070 Intangible asset risk

#### R0100 Basic Solvency Capital Requirement

#### Calculation of Solvency Capital Requirement

R0130 Operational risk

R0140 Loss-absorbing capacity of technical provisions

R0150 Loss-absorbing capacity of deferred taxes

R0160 Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC

#### R0200 Solvency Capital Requirement excluding capital add-on

R0210 Capital add-ons already set

R0220 Solvency capital requirement

#### Other information on SCR

R0400	Capital requirement for duration-based equity risk sub-module
R0410	Total amount of Notional Solvency Capital Requirements for remaining part
R0420	Total amount of Notional Solvency Capital Requirements for ring fenced funds

R0430 Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios

R0440 Diversification effects due to RFF nSCR aggregation for article 304

Gross solvency capital requirement	USP	Simplifications
C0110	C0090	C0120
12,002		
2,047		
0		
0		
27,991		
-7,845		
0	USP Key	
	For life underw	riting risk:
34,195	1 - Increase in th benefits 9 - None	ne amount of annuity
C0100	For health unde	rwriting risk:
1,274		ne amount of annuity

1 - Increase in the amount of a benefits 2 - Standard deviation for NSLT

2 - Standard deviation for NSLT health premium risk

3 - Standard deviation for NSLT health gross premium risk

4 - Adjustment factor for non-proportional reinsurance

5 - Standard deviation for NSLT health reserve risk

9 - None

0

0

0

0

0

0

0

0

0

35,469

35,469

#### For non-life underwriting risk:

4 - Adjustment factor for non-proportional reinsurance

6 - Standard deviation for non-life premium risk

7 - Standard deviation for non-life gross premium risk

8 - Standard deviation for non-life

### S.28.01.01 Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

	Linear formula component for non-life insurance and reinsurance obligations	C0010		
R0010	MCR <sub>NL</sub> Result	6,854		
			Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
			C0020	C0030
R0020 R0040 R0050 R0060 R0070 R0080 R0090 R0100 R0110 R0120	Medical expense insurance and proportional reinsurance Income protection insurance and proportional reinsurance Workers' compensation insurance and proportional reinsurance Motor vehicle liability insurance and proportional reinsurance Other motor insurance and proportional reinsurance Marine, aviation and transport insurance and proportional reinsurance Fire and other damage to property insurance and proportional reinsurance General liability insurance and proportional reinsurance Credit and suretyship insurance and proportional reinsurance Legal expenses insurance and proportional reinsurance Assistance and proportional reinsurance		0 0 0 0 0 0 0 0 38,723 0 0	
R0130	Miscellaneous financial loss insurance and proportional reinsurance		0	
R0140	Non-proportional health reinsurance		0	
R0150	Non-proportional casualty reinsurance		0	
R0160	Non-proportional marine, aviation and transport reinsurance		0	
R0170	Non-proportional property reinsurance		0	
R0200	<b>Linear formula component for life insurance and reinsurance obligations</b> MCR <sub>L</sub> Result	C0040	Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
R0210 R0220 R0230 R0240 R0250	Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations		C0050	C0060
	Overall MCR calculation	C0070		
R0300	Linear MCR	6,854		
R0310	SCR	35,469		
R0320	MCR cap	15,961		
R0330	MCR floor	8,867		
R0340	Combined MCR	8,867		
R0350	Absolute floor of the MCR	2,222		
R0400	Minimum Capital Requirement	8,867		



SFCRAMT00118042019